{
  "name" : "twin.sci-hub.se_6324_ffc4be4901797d2f145629c8572ae462_cai2017.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Programmable Nano–Bio Interfaces for Functional Biointegrated Devices",
    "authors" : [ "Pingqiang Cai", "Wan Ru Leow", "Xiaoyuan Wang", "Yun-Long Wu", "Xiaodong Chen" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "REVIEW\n1605529 (1 of 26) © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de\nProgrammable Nano–Bio Interfaces for Functional Biointegrated Devices\nPingqiang Cai, Wan Ru Leow, Xiaoyuan Wang, Yun-Long Wu,* and Xiaodong Chen*\nDOI: 10.1002/adma.201605529\ndiseases (e.g., diabetes, metastatic cancers, and Parkinson’s disease). As an alter native solution, recent advances of nanotechnology in biomedicine are showing great promise towards advanced screening and shielding systems/devices.\nWith the increasingly extensive application of nanotechnology in biomedical scenarios, the corresponding nano–bio interfaces are also in the spotlight. At the nano– bio interfaces, nanomaterials interact with biological entities at multiple levels (e.g., proteins, DNA, membranes, organelles, cells, tissues, and organs) through a series of dynamic bio-physicochemical interactions, which can be modulated through the programming of various nanomaterials properties, such as surface chemistry, size, shape, dimension scale and topographic structures.[2,3] It is therefore crucial in the study of nano–bio interfaces to control the surface chemical[4–7] and physical\nproperties,[8–11] as well as functionalities[1,12–14] of nanomaterials, in order to modulate their interfacial interactions with bioentities.\nOver the past decades, nanomaterials of multiple dimension scales, ranging from zero-dimensional (0D) nanoparticles (NPs),[14] one-dimensional (1D) nanotubes (NTs),[15] and nano wires (NWs),[16] two-dimensional (2D) graphene[17] and nanomembranes (NMs),[18,19] to three-dimensional (3D) architectured nanomaterials,[20] have been programmed on demand as building blocks for the development of functional biointegrated devices (Figure 1). This is because the dimension scale of nanomaterials confers intrinsic advantages as different functional modules in biointegrated devices. For instance, NPs possess excellent penetration capability, versatility in fabrication, and can be given multiple functionalities via surface modification, which renders them the most well-established nanomaterials to be interfaced with biological entities, especially in the fields of drug/gene nanocarriers[8] and diagnostic probes.[14] Meanwhile, 1D and 2D nanomaterials, such as carbon nanotubes (CNTs) and graphene, exhibit unique electrical behaviors, which can open up new frontiers in nano-bioelectronics for boosting the sensitivity of biosensors and understanding of electrophysiology.[21] 2D layered nanomaterials for nanodiagnostics at molecular and cellular interfaces may also enable flexible and stretchable bioelectronics that are compatible with soft or curvilinear biological structures.[19] Lastly, emerging 3D nanomaterials constitute a strategy for incorporating the advantages of the 0D, 1D, and 2D nanomaterials to enable highly-integrated and sophisticated functional devices that are capable of multitasking.[1,22,23]\nA large amount of evidence has demonstrated the revolutionary role of nanosystems in the screening and shielding of biological systems. The explosive development of interfacing bioentities with programmable nanomaterials has conveyed the intriguing concept of nano–bio interfaces. Here, recent advances in functional biointegrated devices through the precise programming of nano– bio interactions are outlined, especially with regard to the rational assembly of constituent nanomaterials on multiple dimension scales (e.g., nanoparticles, nanowires, layered nanomaterials, and 3D-architectured nanomaterials), in order to leverage their respective intrinsic merits for different functions. Emerging nanotechnological strategies at nano–bio interfaces are also highlighted, such as multimodal diagnosis or “theragnostics”, synergistic and sequential therapeutics delivery, and stretchable and flexible nanoelectronic devices, and their implementation into a broad range of biointegrated devices (e.g., implantable, minimally invasive, and wearable devices). When utilized as functional modules of biointegrated devices, these programmable nano–bio interfaces will open up a new chapter for precision nanomedicine.\nBiointegrated Devices\nDr. P. Cai, W. R. Leow, Prof. X. Chen Innovative Center for Flexible Devices School of Materials Science and Engineering Nanyang Technological University 50 Nanyang Avenue, 639798, Singapore E-mail: chenxd@ntu.edu.sg X. Wang, Dr. Y.-L. Wu Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology School of Pharmaceutical Sciences Xiamen University Xiamen 361102, P. R. China E-mail: wuyl@xmu.edu.cn"
    }, {
      "heading" : "1. Introduction",
      "text" : "In conventional medical systems, a wide range of biological signals are employed for the evaluation of normal organ functions and the diagnosis of diseased tissues, such as physiological (e.g., pulse, temperature), electrophysiological (e.g., electroencephalogram (EEG), electrocardiogram (ECG)), and biochemical cues (e.g., biomarker overexpression, circulating tumor cells).[1] However, these conventional screening systems allow only limited access to target tissues/organs and may be incapable of signal detection with high fidelity and sensitivity for early diagnosis of diseases. In addition, medical intervention enabled by conventional shielding systems may be less potent towards various\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (2 of 26)\nFor example, the integration of therapeutic silica NPs with graphene-based nano-bioelectronic devices could enable the effective sweat monitoring and treatment of diabetes patients.[24] It is clear that the intrinsic properties of nanomaterials of various dimensional scales can be combined to leverage the efficacy of specific biomedical functions.\nThe explosive interest towards the investigation of nanomaterials in biological scenarios at the nano–bio interface can be ascribed to the flourishing integration of nanomaterials in biomedicine, culminating in the development of nanodiagnostics, nanotherapeutics, nanotheragnostics (the coupling of diagnostics with therapeutics in one formulation), and regenerative nanomedicine (Figure 2). Recent advances in nanotherapeutics have demonstrated improved treatment of several medical problems, such as cancer, diabetes, neurodegenerative diseases, and inflammation, through boosting drug efficacy and enabling the programmable delivery of therapeutics. For example, stimuli-responsive nanocarriers with synergistic or sequential systems of therapeutics delivery have been designed for enhanced anticancer therapy, in order to achieve spatiotemporally controlled release and site-specific transport, while mitigating the development of drug-resistance and the subsequent need for higher therapeutic doses.[25] In the field of nanotheragnostics, much attention has been drawn towards multifunctional NPs that combine diagnostic and therapeutic applications by triggering the release of genes or drugs at target sites in response to external stimuli, as these can constitute potent tools for realtime monitoring and understanding the delivery, release, and efficacy of drugs.[13] In regenerative nanomedicine, nanotechnological strategies have been developed, such as recapitulating the nanocomposite nature of tissue scaffolds[26] and monitoring advanced cell therapy.[27] In addition, there has also been an exponential increase in using nanomaterials to study the modulation of biological processes, such as cell migration,[28,29] differentiation,[30,31] and metastasis[32,33] through chemical and physical cues; however, these will not be covered here.\nHere, recent advances in functional biointegrated devices will be discussed with respect to constituent nanomaterials of multiple dimension scales and their respective programmability as different functional modules. Specifically, we will highlight the respective intrinsic advantages of programmable nano–bio interfaces to be applied in biomedicine, as well as their on-demand assembly as functional biointegrated devices. It is believed that such “hierarchical” programming of nano–bio interfaces, coupled with detailed understanding of the interfacial interactions, will open up a new chapter in personalized nanomedicine, in which functional biointegrated devices can be constructed in accordance to specific tissue types and disease conditions."
    }, {
      "heading" : "2. Nanoparticles with Programmable Multifunctionalities",
      "text" : "Over the past decade, NPs have been intensively investigated as advantageous alternatives to conventional diagnosis and therapy methods owing to the following superior features. First, NP-based multifunctional nanoplatforms can be constructed for both diagnosis and therapy, through the incorporation of multiple imaging or therapeutic agents. Secondly, the large compartments of NPs (e.g., large interior cargo volume or high surface area) have enabled the encapsulation of considerable amounts of imaging agents or therapeutics. Thirdly, NPs can specifically accumulate at disease sites through modification with targeting ligands or optimization of size and shape, in\nPingqiang Cai is currently a Research Fellow at the School of Materials Science and Engineering, Nanyang Technological University, Singapore, where he received his Ph.D. degree in 2015 under the supervision of Prof. X. Chen. He received his B.S. degree in materials science and engineering from Jilin University (China) in\n2010. His research interests focus on mechanobiology and biomedical devices.\nYun-Long Wu is currently an Associate Professor at the School of Pharmaceutical Sciences, Xiamen University (China). He received his B.S. degree in materials science from the University of Science and Technology of China in 2005 and Ph.D. degree in bioengineering from the National University of Singapore in 2011. After\nhis postdoctoral fellow training at Nanyang Technological University (Singapore) under the supervision of Prof. X. Chen, he joined Xiamen University as an assistant professor in 2012 and was promoted to the position of Associate Professor in 2014. His research is focused on nanomedicine.\nXiaodong Chen is a Professor at Nanyang Technological University, Singapore. He received his B.S. degree in chemistry from Fuzhou University (China) in 1999, his M.S. degree in physical chemistry from the Chinese Academy of Sciences in 2002, and his Ph.D. degree in biochemistry from the University of Muenster (Germany)\nin 2006. He became an Associate Professor at Nanyang Technological University in 2013 and Full Professor in 2016. His research interests include programmable materials for energy conversion and integrated nano–bio interfaces.\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (3 of 26)\norder to maximize the imaging quality or therapeutic efficacy. Finally, NPs of appropriate size and surface modification may enable prolonged circulation time in the blood.[14]\nRecent advances in nanomedicine are reflective of the development of multifunctional NPs. Initially, these NPs were developed for the targeted delivery of imaging agents. However, each imaging modality alone has its limitations, thereby synergetic multimodal imaging is exploited by incorporating several imaging agents into multifunctional NPs for precise disease diagnosis. Moreover, theragnostic nanoparticles (TNPs) could be developed by incorporating diagnosis and therapy function in a single formulation. Due to these aforementioned unique features, NPs have become competitive candidates for enhanced therapy via personalized medicine.[14] Together, such programmability has endowed multifunctional NPs with a promising future as novel diagnostic and therapeutic modules in functional biomedical devices for nanodiagnostics, nanotherapeutics, and nanotheragnostics."
    }, {
      "heading" : "2.1. Nanoparticles for Nanodiagnostic Probes",
      "text" : ""
    }, {
      "heading" : "2.1.1. Multimodal Nanodiagnostics",
      "text" : "Each single imaging modality has its unique merits while subject to various intrinsic limitations (e.g., inadequate sensitivity\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (4 of 26)\nor spatial resolution), which renders it challenging for one single imaging modality to retrieve accurate and comprehensive clues about a disease scenario.[14] For example, computed tomography (CT) and magnetic resonance imaging (MRI) can yield anatomical information of high spatial resolution, whereas positron emission tomography (PET) can offer functional information about the diseased tissues with high sensitivity. Therefore, to obtain detailed anatomical or functional information of the disease, with both high sensitivity and high resolution, the recruitment of different imaging modalities would be necessary. To this end, a variety of NPs have been developed as nanoscale multimodal imaging probes, such as optical/MRI, optical/CT, optical/PET, and PET/CT. The rationale behind the design of these multimodal imaging probes is to combine imaging modalities of high sensitivity (optical, PET, etc.) with imaging modalities of high resolution (MRI, CT, etc.), in order to prevent an overlap in advantages and to recompense the drawbacks of each single imaging modality for the maximization of the synergistic effect.[14] An example of the ideal multimodality is demonstrated by an AuNP-based dual imaging probe combining CT and optical imaging, which takes advantage of AuNPs X-ray absorption and optical quenching properties (Figure 3a).[34] Although a biological process or a diseased lesion cannot be observed by CT imaging, since soft tissue absorbs little X-ray, Ahn et al. solved this problem by introducing AuNPs as a contrast agent for CT imaging and as a fluorescence probe for optical imaging. AuNPs were firstly modified by glycol chitosan (GC-AuNP), followed by the conjugation of matrix metalloproteinase (MMP)-sensitive peptide probes to GC (MMP-GC-AuNP). While the increased X-ray absorption by AuNPs allows for contrasted CT imaging of the tumor, optical imaging is initiated through the fluorescence recovery of Cy5.5 upon the substrates degradation by MMP. In this way, dual modality imaging (optical/CT) of cancer is realized by the in vivo\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (5 of 26)\naggregation of MMP-GC-AuNP in the tumor. Recently, Blower et al. have demonstrated an alternative way of radio-labeling iron oxide nanoparticles (IONPs) with 64Cu for MRI/PET dual modality imaging (Figure 3a).[35] A novel bifunctional chelator, bis(dithiocarbamatebisphosp honate) ((DTCBP)2), was developed for the radio-labeling of IONPs with 64Cu. In (DTCBP)2, the dithiocarbamate group acted as a chelator for binding the target, while the bisphosphonate groups were directly bound to the IONPs surfaces. The obtained dual MRI/PET imaging probes by such radio-labeling of clinical IONPs (Endorem/Feridex) were proven to be effective in the detection of lymph nodes. In another MRI/PET dual modality probe, the surfaces of the IONPs were labeled directly with the 124I radioisotope.[36] This concept has also been extended to triple modal imaging by the conjugation of PET probes to dual MRI/optical probes.[37]"
    }, {
      "heading" : "2.1.2. Responsive Nanodiagnostics",
      "text" : "By tailoring the physiochemical interactions at the nano–bio interfaces, the capabilities of smart NPs in biomedical applications have been further boosted due to their programmable response to diverse stimuli,[5] such as light irradiation, thermal treatment, pH value, or the controllable binding and releasing of biomolecule. Such responsive NPs mimic the behavior of living systems, which can undergo rapid and reversible conformational or chemical changes when the physiological microenvironment alters. These NPs are playing crucial parts in a variety of biomedical applications, including controllable biosorting, delivery of diagnostic and therapeutic agents, biosensors, and actuators.[5] Two typical examples of responsive nanodiagnosis include the detection of pathological signatures for disease diagnosis and the evaluation of therapy efficacy (Figure 3b).\nThe ability of AuNPs to perform highly efficient fluorescence quenching is extensively employed as a strategy for responsive nanodiagnosis.[38] Mirkin et al.[39] utilized novel oligonucleotide-modified AuNP probes as transfection agents and “nanoflares” to evaluate intracellular RNA release. To construct nano-flares, AuNPs were functionalized with thiolated oligonucleotides recognizing a specific RNA transcript, followed by the introduction of short reporter sequences terminated with cyanine (Cy5) dye (Figure 3b). When bound to the AuNP surface, the Cy5 fluorescence is quenched. When exposed to a target, the “flare” strand lights up upon its release from the AuNP upon the formation of a longer and more stable duplex between the oligonucleotide-modified AuNP and the target. These nanoflares showed low background noise and were sensitive to the quantity of intracellular RNA transcripts.\nAnother example of responsive nanodiagnosis is the use of a semiconducting-polymer-based nanosensor (SPN) for realtime monitoring of drug-induced in vivo reactive oxygen species (ROS) and reactive nitrogen species (RNS) for evaluating hepatotoxicity directly.[40] Rao et al. have combined fluorescence resonance energy transfer and chemiluminescence resonance energy transfer (Figure 3b) for the simultaneous and differential detection of RNS and ROS via two separate optical windows. The rational coupling of these optical molecular imaging methods with livertargeted SPNs has been demonstrated by simultaneous real-time\ndetection of ONOO– and H2O2 in the liver of living mice. This has successfully found application in the monitoring of in vivo drug-induced hepatotoxicity. In addition, SPNs were also utilized for detecting in vivo ROS and RNS after systemic bacterial infections,[41] as well as for imaging deep-tissue tumors.[42]"
    }, {
      "heading" : "2.1.3. Innovative Nanodiagnosis",
      "text" : "Biomarker identification is becoming increasingly important for clinical risk assessment, early detection of diseases, evaluation of therapy outcome, and the surveillance of recurrent diseases. However, fundamental technical and biological challenges limited the detection of endogenous biomarkers, due to their low concentrations in the circulation, their degradation both in vivo and ex vivo, and the difficulty in resolving in complex biological fluids. For example, the low concentration of cancer biomarkers in serum hinders their use in early cancer detection. Therefore, it becomes necessary to develop probes capable of sensing cancer biomarkers at ultralow concentrations (106 times lower than other blood proteins). To address this challenge, Tamayo et al.[43] combined mechanical and optoplasmonic transduction in a hybrid assay for detecting ultralow cancer biomarkers as sparse as 1 × 10–16 g mL–1 in serum (Figure 3c). Biomarkers (carcinoembryonic antigens or prostate specific antigens) are first captured by an antibody anchored to the silicon cantilever surface and then by the antibody-tethered AuNPs in solution that recognize a free site of those biomarkers, in which the AuNPs function as a mass and plasmonic label. The silicon cantilever was used to detect these two signatures, which acts as a mechanical resonator and as an optical cavity. This hybrid assay could significantly improve biomarkers detection sensitivity and can be used in routine blood tests for early-cancer detection. In addition to recognizing such cancer biomarkers in serum, the detection of circulating tumor cells (CTCs) is also significant in early cancer diagnosis.[44–47] Toner et al.[48] have developed the “CTC-iChip” for isolating rare CTCs out of whole blood at 107 cells s–1, taking advantage of magnetic-based cell sorting in combination with the benefits of microfluidics for coping with rare cell separation. It has been shown that the incorporation of nanostructures could significantly leverage the biomarker recognition capabilities of CTC capture devices for early cancer diagnosis.[49–52]\nIn order to provide an alternative to endogenous biomarkers, there has been an emergence in the systemic administration of exogenous agents to investigate biological states. Bhatia et al.[53] have constructed synthetic biomarkers (mass-encoded peptides bound to NPs) for noninvasive multiplexed urinary monitoring of disease (Figure 3c). The engineered nanoscale synthetic biomarkers passively aggregate in diseased sites via the host circulation. Upon reaching the targeted diseased site, their cleavage by aberrant proteases releases the mass-encoded peptides into the host urine for the diagnosis of disease by mass spectrometry. This approach has been applied to noninvasively detect early stage cancers and monitor liver fibrosis, which can be further extended for multiplexed urinary monitoring in a wide range of human diseases.[53] In addition, Chiles et al.[54] also developed a molecular-imprint nanosensor for the label-free and ultrasensitive detection of proteins.\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (6 of 26)"
    }, {
      "heading" : "2.2. Nanoparticles as Smart Nanocarriers for Nanotherapeutics",
      "text" : "Nanocarriers (e.g., liposomes, polymeric and inorganic NPs) have been extensively applied to targeted drug delivery with notable advantages, including good biocompatibility, tailorable size and shape, versatile encapsulation strategies and high loading capacity, and stimuli-responsive release with programmable spatiotemporal precision.[55] Nanocarriers also significantly boost the efficiency of targeted drug delivery to pathological tissues and avoid accumulation in healthy tissues, which is primarily based on the “enhanced permeability and retention” (EPR) effect and refers to NPs smaller than 200 nm. Additionally, their hydrophilic surfaces can be more permeable to tumor tissue, as defective tumor blood vessels have a larger endothelium gap. As a result, these properties are setting the gold standard for designing nanocarriers.[56] EPR renders nanotherapeutics with a prolonged blood circulation time, decreased volume of distribution, and reduced renal excretion, which are advantageous over conventional therapeutic drugs. These features allow the NPs to keep active drug concentrations in a therapeutically desirable range with increased solubility, stability, permeability, and selectivity of the laden drugs. Furthermore, the improved delivery efficiency of nanocarriers makes them readily programmed to co-deliver two or more different drugs, which would reduce the administration dosage and multidrug resistance effect. An example of a nanocarrier is mesoporous silica nanoparticles (mSNs), which has been intensively investigated for biomedical applications due to its advantageous tailorable mesoporous structure, high pore volume, and large surface area. These mSNs are exploited to transport a variety of therapeutic agents[57] to targeted disease sites. More recently, self-assembled DNA nanostructures are becoming novel nanocarriers for targeted drug delivery. Although naked DNA molecules have difficulty in crossing the cell membrane, many DNA nanostructures (e.g., DNA nanotubes, tetrahedra, and origami nanorobot) are able to enter cells with high uptake efficiency. These DNA nanostructures can therefore be applied as drug delivery nanocarriers for therapeutic applications and gene regulation.[58]\nNot only that, nanocarriers can be tailored to deliver therapeutics as a response to external and internal triggers, in order to further improve the efficacy of therapy. Examples of internal stimuli are decreased pH, reducing environment, and enzymatic activity, while external triggers consist of light, temperature, magnetic field, ultrasound, and X-rays. Various NPs have been tailored for pH-responsive nanocarriers, and the incorporation of photosensitizers and photothermal effectors further renders the nanocarriers capable of photodynamic therapy (PDT) and photothermal therapy (PTT). Sophisticated systems with different modes of complex release actions have also been developed, such as synergistic and sequential strategy, which will be elaborated on in the following sections.[25]"
    }, {
      "heading" : "2.2.1. Synergistic Strategy",
      "text" : "The synergistic approach introduces combination therapy that simultaneously delivers more than one therapeutic agent to achieve synergistic efficacy, in order to overcome multidrug\nresistance and to lower the effective dosage. Although NPsbased nanocarriers have enabled targeted delivery of therapeutic agents into tumors and subsequent tumor-selective drug release, the efficacy may still be limited because cancer cells are able to develop resistance to chemotherapy and metastasize to form secondary cancer. Therefore, a synergistic strategy that aims at a different aspect of the cancer mobility is urgent. A photoactive multi-inhibitor nanoliposome (PMIL)[59] has been developed, which incorporates light-induced PDT by a nanoliposome decorated with a photoactive chromophore (benzoporphyrin derivative, BPD) and synchronic treatment by photo initiated and sustained inhibitor release. In this case, a PMIL containing a multikinase inhibitor (cabozantinib, XL184) was used to suppress tumor regrowth and metastatic escape signaling pathways (Figure 4a). After intravenous PMIL administration, NIR tumor irradiation initiates the release of XL184 into the tumor, which also introduces photodynamic therapy, damaging the tumor and microvessels. Prolonged tumor reduction and suppressed metastatic escape have been successfully achieved with a single PMIL treatment. Another practice of synergistic strategy is to integrate multimodal therapies (e.g., chemotherapy, irradiation therapy, thermotherapy, etc.) in a single formulation. An AuNP-based cancer treatment has been developed using a quadrapeutic system,[60] comprising gold colloids, chemotherapeutic agents, laser pulses, and X-rays (Figure 4a), which combines on-demand chemotherapy and irradiation therapy. The AuNPs were functionalized to specifically target aggressive cancer cells via the overexpressed epidermal growth factor receptor, and were simultaneously incubated with targeted drug nanocarriers. The AuNPs and nanocarriers subsequently self-assembled to form nanoclusters (Figure 4a) upon cellular endocytosis. The formed nanoclusters were then excited with localized laser pulses and X-ray irradiation to trigger three intracellular therapeutic actions: i) mechanical impact of vapor plasmonic nanobubbles (PNBs); ii) subsequent drug release from PNB-disrupted nanocarriers; and iii) amplification of X-ray irradiation localized at tumor sites. These three intracellular therapeutic events resulted in obvious tumor regression, in contrast to the effect of monotherapies. Importantly, the threshold energy for PNB formation is significantly higher for single NPs or smaller clusters, which are non-specifically accumulated in normal cells, therefore, only cancer cells can selectively generate PNBs at low laser energy.[61] Similarly, other AuNP-based combinational therapies are promising in cancer treatment, as these reduce multidrug resistance and drug administration dosage.[25,61]"
    }, {
      "heading" : "2.2.2. Sequential Strategy",
      "text" : "In contrast to the synergistic strategy, the sequential approach is for NPs to incorporate multiple elements that sequentially respond to a variety of stimuli, thus breaking down the physiological barriers in the delivery path to achieve a more precise, targeted delivery. Early pH-responsive nanocarriers are triggered by either the intracellular or the extracellular pH condition of tumor cells. However, these nanocarriers suffer from impaired drug delivery efficacy. The nanocarriers that target the extracellular pH release the laden therapeutics extracellularly, resulting\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (7 of 26)\nin a reduced efficacy towards eradicating drug-resistant tumor cells, while those responsive to the intracellular pH encounter a heavily reduced uptake efficiency. This challenge can be overcome through the design of dual pH-responsive NPs[62] that are responsive to both the extracellular and endo-/lysosomal pH, thus enhancing drug delivery efficacy. In the extracellular pH (≈6.8) environment of the tumor, the surface charge of polymeric NPs can be shifted from negative to positive to facilitate cellular internalization. Once the NP is trapped in the endosome, the acidity (pH ≈ 5.0) increases significantly, which further triggers doxorubicin release. These dual pH-responsive NPs have exhibited great potential for eliminating drug-resistant cancer stem cells (Figure 4b). Conjugation of multiple targeting moieties that recognize different subcellular structures is another way of sequential strategy. To this end, a carrier for sequential specific delivery of doxorubicin into the nucleus has been developed, which modifies mesoporous silica nanoparticles (MSNs)[63] with moieties for targeting cell and nuclear membranes (Figure 4b). In these MSNs, RGD peptides were incorporated for enhanced cellular uptake upon overexpressed integrin αvβ3 receptors on the cancer cell membrane, and Tat peptides were also conjugated for more efficient nuclear internalization. These modifications enable efficient cellular uptake and enhanced nuclear penetration of the MSNs, which allows effective delivery of the chemotherapeutic agents into the cell nucleus and therefore significantly increased cytotoxicity to cancer cells."
    }, {
      "heading" : "2.3. Nanoparticles for Multimodal Nanotheragnostics",
      "text" : "Biomedical NPs have contributed to the explosive development of both nanotherapeutics and nanodiagnostics in the past decades. Recently, the multifunctionality of NPs enabled the combination of diagnosis with therapy to form clinically\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (8 of 26)\neffective formulations for targeted drug delivery, visualization of drug release, and therapeutic efficacy.[14,64] This emerging field is coined as “theragnostics”, and is expected to further optimize the therapeutic efficacy by using diagnostic information to achieve personalized medical care.[65] Therefore, theragnostic nanoparticles (TNPs) combine targeted drug delivery, environmentally responsive drug release, and drug efficacy evaluation in one single formulation. To this end, two different approaches are employed for combining disease diagnosis and therapy into a single NPs-based system. In the first approach, imaging or diagnostic agents are introduced into classical drug delivery systems (e.g., liposomes, polymeric NPs, micelles, DNA NPs, etc.). In the second, NPs with the intrinsic capability of imaging or diagnosing (such as AuNPs and IONPs) are further modified for the delivery of therapeutic agents. TNPs are highly tailorable nanomaterials for monitoring the delivery, release, and therapy efficacy of incorporated therapeutic agents. So far, imaging modalities that have been incorporated in TNPs include optical imaging, MRI, PET, CT, near-infrared fluorescence (NIRF), single-photon emission computed tomography (SPECT), and ultrasound imaging. The incorporation of multiple imaging agents into TNPs have also been achieved to utilize the advantages and mitigate the disadvantages of each imaging modality.[65] Photosensitizers not only function as light-sensitive drugs, but also exhibit intrinsic fluorescence, which permits monitoring of their biodistribution without further labeling.\nWith the development of TNPs, it becomes necessary to noninvasively track the circulation and accumulation of nanocarriers in real-time, to facilitate pharmacokinetic and biodistributional analysis of the formulations, and to accordingly improve drug delivery to diseased tissues.[13] A variety of TNPs have been developed for this reason. An example is a multifunctional hollow mesoporous silica nanocage system[66] loaded with FITC for intracellular tracking by fluorescence imaging. The chemotherapy drug DOX could be effectively encapsulated in the silica nanocages, which could be released via the pores in response to the acidic pH conditions in cancer cells. PDT could also be achieved through the further conjugation of hematoporphyrins that act as photosensitizers upon UV irradiation. In another example, MSNs were combined with IONPs for simultaneous drug delivery, fluorescence imaging, and MR imaging.[67] The MSNs could either possess an iron oxide core or be doped with IONPs on the outer surface. These MSNs have simultaneously achieved drug delivery with DOX, optical imaging with the RTIC dye, and MR imaging with IONPs. A comparative study also demonstrated the necessity for combining drug delivery with biodistribution of the released drugs, rather than with nanocarriers.[68] Comparison was made between the physical loading and chemical conjugation of the photosensitizer chlorin e6 (Ce6) into glycol chitosan NPs; significant differences could be observed in the biodistribution and target accumulation of Ce6 (Figure 5a). More interestingly, different therapeutic efficacies were caused by disparity in the in vivo distribution of drugs. In another case, multifunctional TNPs were loaded with the dye NIRF (IR-780 iodide) for both NIRF imaging and photothermal therapy, as well as with the recently developed radionuclide rhenium-188 (188Re)[69] for noninvasive monitoring of the real-time biodistribution of drug\ncarriers. The biodistribution of the TNP nanocarriers and the released therapeutic agents were significantly different. This result highlights the necessity for real-time monitoring of drug delivery to ensure the effectiveness of therapy.\nIn addition to precise delivery to pathological sites, the loaded therapeutic agents need to be efficiently released in order to achieve effective therapy. It is of utmost significance to monitor drug release from TNPs, since drug release patterns vary greatly between formulations.[13] Pioneering efforts in this regard used manganese sulfate for both encapsulation of doxorubicin into liposomes and noninvasive visualization of drug release; MRI signals were generated and increased upon the simultaneous disassembly of MnSO4 and doxorubicin.[70] Multi functional theragnostic NaYF4:Yb/Tm@NaGdF4 core/hollow MSNs have also been developed, which utilize dual-mode MRI and unconverted luminescence imaging to simultaneously achieve NIR-triggered drug delivery and in situ monitoring of drug release.[71] Most recently, dipeptide (tryptophan–phenylalanine) nanoparticles (DNPs) loaded with DOX have been developed for targeted cancer cell imaging and drug release monitoring in real-time.[72] Previously, intrinsic optical properties (fluorescence signal in the ultraviolet range) of peptide nanostructures have restricted their applicability in biomedical applications as productive imaging probes. However, the formation of DNPs renders peptides photostable and biocompatible, while possessing visible fluorescence within a narrow emission bandwidth, which renders DNPs an ideal imaging and sensing probe. More importantly, DNPs modified with the MUC1 aptamer and DOX are not only capable of targeted drug delivery, but also real-time monitoring of drug release through mutual quenching between DNPs and DOX (Figure 5b).\nBesides the noninvasive monitoring of drug delivery and release, the multifunctionality of TNPs can be further leveraged for the prediction and monitoring of therapeutic efficacy. Several organic prodrugs have already been successfully developed by integrating targeted delivery, monitoring of drug release, and in situ evaluation of therapy effects.[73,74] However, intrinsic disadvantages, including limited circulation time and the necessity to penetrate the blood-brain barrier (BBB), may impair in vivo applications. To counter this, a promising solution has been developed using integrated NIR-activatable nanomaterials:[75] a photoactivatable platinum(IV) prodrug is incorporated into silica-coated upconversion-luminescent NPs (UCNPs), conjugated with caspase imaging peptides, in order to simultaneously realize the remote activation of the antitumor prodrug and the real-time monitoring of apoptosis, to evaluate efficacy of the activated prodrug (Figure 5c). Importantly, such selective activation by NIR of a potent PtII complex at tumors sites can maximize the efficacy of penetrable light while bypassing nonspecific damage to normal tissues. More recently, a metal– organic framework TNP cage[76] has been developed for highly efficient anticancer therapy and in situ monitoring of the therapeutic efficacy through caspase-3 detection, by integrating a photosensitizer porphyrin for increased singlet oxygen quantum yield, a folate targeting ligand, and a dye-labelled peptide. These examples have demonstrated the promising potential of incorporating therapy efficacy monitoring in TNPs for precise disease diagnosis and treatment.\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (9 of 26)\nIn stem cell therapy, the potential linage specification of stem cells into multiple defective cell types and/or induced regenerative processes through paracrine mechanisms[77] renders them capable of treating a variety of injuries (i.e., stroke, myocardial infarction, and bone fractures), degenerative diseases (i.e., Parkinson’s disease), and injured tissues, such as in spinal cord repair. In order to assess and enhance the therapeutic efficacy, reliable cell trackers are essential for monitoring the cellular biodistribution, engraftment, and fate of transplanted stem cells, without undermining their\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (10 of 26)\nbiofunctions.[27] To this end, the magnetic labeling of stem cells has been extensively investigated by adding various superparamagnetic iron oxide nanoparticles (SPIONs) for non-invasive MRI, with high repeatability and spatial resolution.[78] Recently, ultrastable conjugate polymer Tat-PFBD nanodots were applied to tracking of long-term stem cells. By using a mouse model with full-thickness skin wounds, the mechanism of how transplanted stem cells promote wound healing was revealed.[79]\nIn short, the above discussion has highlighted the potential of NPs in nanodiagnosis, nanotherapeutics, and nanotheragnostics. Beyond these areas, NPs can also find important applications in the implementation of bionic organs, which has tremendous impact in prosthetics and regenerative medicine, due to their potential to replace dysfunctional parts of the human body.[80] To sum things up, NPs are programmed in the aspects of size, surface chemistry, and composition, as well as encapsulation of versatile pharmaceuticals and advanced release strategies (e.g., sequential and synergistic delivery), and the smart integration of multifunctionalities (e.g., multimodal imaging, TNPs). Its role as therapeutic and diagnostic modules in functional biointegrated devices is promising. Finally, safety and efficacy, in terms of the biodistribution, immune toxicity, or degradability of NPs, should also be carefully tested before any animal or clinical studies.[81] Unfortunately, current regulatory standards for safety consideration of nanomedicine are greatly delayed in terms of using NPs as a specific class of therapeutic or diagnostic agents, which requires further efforts."
    }, {
      "heading" : "3. Nanorods, Nanotubes, and Nanowires Tailored for the Biosensing Module",
      "text" : "In addition to NPs, 1D nanomaterials, such as nanorods (NRs), NTs, and NWs, have gained great interests in biomedical applications, due to their similarities to the structures of\nnatural biomaterials (e.g., silk, keratin, tubulin, actin, etc.), unique cellular uptake mechanisms, and optical and electronic responses. However, pristine 1D nanomaterials can encounter problems with bioincompatibility. Interestingly, recent research has revealed that a novel class of bioactive NRs or NTs can be achieved by biofunctionalization of these 1D nanomaterials with carbo hydrates, proteins, or nucleic acids, which provides exciting tools for modulating the behaviour of biological cells. The following section highlights recent developments of biofunctionalized 1D nanomaterials, with a focus on nanointerfaces, for applications in nanodiagnosis, nano-bioelectronics, and nanomedicine."
    }, {
      "heading" : "3.1. Nanorods and Nanotubes as Multifunctional Nanotheragnostic Probes",
      "text" : "NRs and NTs offer sensitive, cost-effective, and rapid approaches to nanotheragnostics, due to their advantages of aspect ratio-induced cellular uptake enhancement, unique Raman scattering,[82] and plasmonic photothermal effect.[83] As a typical example, Raman scattering signals can be greatly increased (up to 105 fold) due to local electromagnetic field enhancement by surface plasmon excitation of AuNRs. Due to their aspect ratio and facile shape control, AuNRs with tunable surface plasmons have been successfully applied in multi modal sensing and photothermal therapy. Sailor et al.[82] have designed an interesting nanotheragnostic system based on AuNRs and temperature-responsive liposomes containing chemotherapeutic molecules. In this case, AuNRs were modified by poly(ethylene glycol) (PEG) on their surfaces to avoid non-specific binding, which were further attached to a cyanine dye to produce SERS-responsive probes for high contrast tumor imaging (Figure 6). At the same time, chemotherapeutic drugs were spontaneously released from thermoresponsive liposomes upon local infrared laser irradiation. Thanks to the passive accumulation of PEG-AuNR through intravenous injection,\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (11 of 26)\nthe MDA-MB-435 xenografted tumor site could be visible by using a SERS spectrum. Furthermore, the on-demand release of anticancer drugs upon local heating led to significant inhibition of tumor growth, which shows the importance of AuNRs in nanotheragnostics. More interestingly, recent work revealed that single AuNR-based theragnostic probes could be achieved by carefully embedding these into a single capsule using a 3D printing technique, which allowed a more sensitive spatiotemporal response over biomolecular gradients.[83]\nAnother example is CNTs, which are cylindrical tubes of interconnected benzene rings. CNTs are promising for diagnosis or imaging because of their high near-infrared NIR absorption, strong Raman shift, photothermal ability, and photo acoustic property. To this end, Dai et al.[84] developed single-walled carbon nanotubes (SWCNTs) modified by polymeric PEG for reducing non-specific binding, followed by conjugation with tumor targeting RGD peptides. Interestingly, the obtained SWCNTs labeled with 64Cu were utilized to achieve in vivo biodistribution imaging by PET and ex vivo visualization by Raman spectroscopy, thanks to the CNTs’ intrinsic Raman shift. Experimental results showed highly effective accumulation of SWCNTs in the tumors of living mice, with high expression of RGD peptide specific integrin α5β3 membrane receptors, indicating the great potential for CNTs in the diagnosis of cancer. In contrast to enhanced Raman scattering by AuNRs, Gambhir et al.[85] showed that SWCNTs, biofunctionalized with RGD peptides for tumor tissue recognition, could also be utilized for photoacoustic imaging or as contrast agents without any dyes. This rendered SWCNTs greatly promising for in vivo multimodal imaging of tumors, as photoacoustic imaging through responsive ultrasonic signals triggered by shortpulsed laser irradiation could provide deep tissue images with high spatial resolution compared to traditional fluorescence imaging. Meanwhile, Dai et al.[86] showed that SWCNTs could also provide optical images of internal diseased tissue due to their high NIR optical absorption. Because NIR light is highly permeant to biological tissues, SWCNTs showed great advantages in disease diagnosis. Besides nanodiagnostics, CNTs also possess advantages that make them ideal for nanotherapeutics, such as the capability of drug loading by encapsulation, surface attachment or entrapment, and good cell membrane barrier penetration for efficient drug accumulation at the target site. Bianco et al.[87] demonstrated that functionalized CNTs were highly permeant through cellular barriers in many biological cells. To be highlighted, CNTs with surface biomodification could achieve intracellular trafficking in just a few hours due to receptor-mediated endocytosis or phagocytosis for effective cell uptake. More interestingly, the report also showed that biomodified CNTs could overcome cellular barriers and be taken up by mammalian and prokaryotic cells, in a manner analogous to a “nanosyringe”, using energy-independent approaches, thanks to their cylindrical geometry, thus enabling high penetration rates through the plasma membrane. Further study revealed that their cellular uptake might be passive and endocytosis independent,[88] as cell penetration was not affected by the introduction of endocytosis inhibitors. Dai et al.[89,90] demonstrated that short SWNTs were highly efficient in transporting proteins and oligonucleotides through clathrin-coated pit-mediated endocytosis without lipid rafts or caveolae. As a result, SWCNTs\nwith noncovalent absorbed oligonucleotides were effective for gene delivery coupled with photothermal release. Upon effective cellular membrane penetration, SWCNTs could absorb NIR irradiation and trigger intracellular endosomal rupture, which lead to fast release of genes for intracellular protein expression. In addition to oligonucleotides, Dai et al.[86,91] also developed SWNTs as nonviral short interfering RNA (siRNA) carriers, which were introduced into primary human cells but were ineffective in transfection. Interestingly, nanotubes exhibited better RNA interference efficiency over existing liposome-based nonviral transfection vectors, indicating its unique gene transportation ability in biologically important cells. Lastly, Rusling et al.[92] showed that SWCNTs conjugated to chemotherapeutic cisplatin could be intravenously injected into nude mice with solid tumors, which achieved significant shrinkage of the tumors, indicating the promising role of SWCNTs in cancer therapy."
    }, {
      "heading" : "3.2. Nanowires and Nanotubes as Versatile Nanoelectronic Biosensors",
      "text" : "In addition to fluorescent or spectrum sensors, 1D nanomaterials have also been widely utilized in nano-bioelectronics.[21] Nano-bioelectronics refers to an expanding interdisciplinary field that combines nanomaterials with biology and electronics, in order to overcome current challenges in bioelectronics and open up new frontiers in fundamental biology and healthcare. In addition to affinity-based protein or DNA sensors, nano-bioelectronic devices interfaced with electrogenic cells (e.g., neurons or cardiomyocytes) can also shed a light on cellular electrophysiology.[22,93]\nSilicon nanowires (SiNWs) constitute a representative example of 1D nanomaterials used in bioelectronics. The modulation of their nanostructure properties, such as morphology, size, composition, and doping, have been widely investigated and can be precisely controlled during either top-down or bottom-up synthesis.[94–96] Silicon and other NWs can be wellaligned into highly ordered arrays, which is important for construction of arrays of bioelectronic devices and integrated circuits.[97] On the molecular level, Lieber et al.[98] first exhibited a pH nanosensor (Figure 7a) based on amine-functionalized SiNW solid state field-effect transistors (FETs), as well as cancer protein markers (i.e., prostate specific antigen (PSA))[99] (Figure 7b) based on PSA-Ab1-modified p-type SiNWs. These sensors represent a new label-free biological or chemical molecule detection approach with promising applications in array-based screening or in vivo diagnostics. On the cellular level, Lieber et al.[100] applied FET arrays based on SiNWs for recording the electrical activities of live mammalian neurons (Figure 8a). It was possible to achieve multisite recording from single neurons by multiple SiNW FET devices, as multiple junction points could be form between the NW device and axon or dendrite. In the proper configuration, the array of SiNW FETs could even be used to study the sensitive spike propagation in axons and dendrites. Interestingly, this approach was further extended as an integrated device consisting of 50 independent NW−axon components for a single neuron study, which enabled multiplex neuron recording using SiNW FET sensors with subcellular spatial resolution. In addition to single neuron electrophysiology, a novel fiber nanoelectrode was designed\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (12 of 26)\nby Huang et al.[101] to amperometrically detect signals from single synapses and to probe single vesicular exocytotic events (Figure 8b). This endeavor enabled direct observation of important physiological events, which might provide a new approach to study the mystery of synaptic communications.\nRecent developments of mechanotransduction—a cellular conversion of mechanical stimuli into biochemical responses—raised the requirement for stretchable sensors that allow detection of important biomolecules during a cell or tissues mechanical deformation process. Huang et al.[102] developed a breakthrough in this field, whereby Au nanotube arrays with a high aspect ratio were used as a novel stretchable electrochemical sensor (Figure 8c). Interestingly, endothelial cells with mechanical sensitivity could be cultured on this biocompatible Au nanotube sensor, which was utilized to detect the release of in vitro nitric oxide (NO) release upon cell stretching. Furthermore, rolling up of Au nanotube sensors enabled interfacing with elastic human veins and represented pioneering work on real time NO monitoring in tissues.\nBesides the aforementioned biosensors, conductive 1D nanomaterials can also be utilized as neural cell culture substrates. As a typical example, a primary hippocampal neuron cell culture was successfully achieved by Papura et al.[103] using chemically modified MWCNTs as the substrate for charge modulation, with clear observation of neuronal branching.\nSimilarly, Kotov et al.[104] applied biocompatible SWCNTs as the substrate for the growth of NG108-15 neuroblastoma cells, with preservation of neurite outgrowth. More interestingly, cellular neurophysiological activity could also be stimulated by underneath SWCNT with excellent electrical conductivity.[105] These elegant examples strongly demonstrate the potential applications of CNTs in future therapeutic settings.\nIn brief, while the optical response (e.g., SERS, NIR) of 1D nanomaterials have rendered them as another class of unique multifunctional theragnostic probes, their excellent electronic properties further allow the monitoring of cell/tissue electrophysiology. More importantly, the programming of conductive 1D nanomaterials by tailoring their shape, surface chemistry, and assembly, would permit the use of high performance nanoelectronics-based biosensing modules in functional biointegrated devices."
    }, {
      "heading" : "4. Layered Nanomaterials Facilitating",
      "text" : "Device Integration\n2D layered nanomaterials are favorable for integration into advanced bioelectronic or optoelectronic devices for biomedical applications, due to their ultrathin thickness and high surface area in planar topography. Biocompatible graphene and its\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (13 of 26)\nanalogues (e.g., transition metal dichalcogenides, transition metal oxides, Bi2Se3, BN, and C3N4 nanosheets) are promising for biomedical applications, including diagnostic (MRI, optical, photoacoustic, and CT imaging) to therapeutic (chemotherapy, photothermal, and photodynamic or synergistic therapies) and theragnostic applications.[17] Meanwhile, semiconductor nanomembranes (NMs) with 2D planar topography, such as MoS2 NM[106] and silicon NM,[107] have also been incorporated into advanced bioelectronic and optoelectronic devices.[19] Similarly, 2D gold nanobelts[108] and PbZrXTi1-XO3 nanoribbons[109] were also developed for the investigation of electrophysiology. The following sections will cover typical examples of 2D nanomaterials in nanomedicine and nano-bioelectronics."
    }, {
      "heading" : "4.1. Layered Nanomaterials for Nanotherapeutics/ Nanotheragnostics",
      "text" : "Graphene is a carbon nanosheet of honeycomb shape that has the ability to assemble into architectures with high aspect ratios. Interestingly, due to its high aspect ratio, graphene allows high loading of many anticancer drugs (e.g., doxorubicin (DOX), whose chemical structure comprises several benzene rings) by π–π stacking.[110,111] As a typical example, Dai et al.[110] showed that graphene conjugated with Rituxan, a specific B-cell antibody, could serve as a targeted drug carrier with the ability to deliver high amount of DOX to B lymphocytes (Raji cells). In addition to pristine graphene, Gu et al.[111] demonstrated\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (14 of 26)\nthat graphene oxide (GO) could also co-deliver ligands of cell death receptors and chemotherapeutic agents. For example, TRAIL apoptosis ligands related to a tumor necrosis factor were conjugated to GO nanosheets using a furin-cleavable peptide as a linker. DOX then self-assembled onto the GO nanosheets at a loading rate of up to 43.8% through π–π stacking. Upon binding of TRAIL to cell death receptors and peptide linker digestion by furin, the DOX loaded GO nanosheets could enter cancer cells via endocytosis and then release DOX inside the cells to achieve enhanced chemotherapy.\nIn addition to its role as a 2D nanocarrier of pharmaceutics, graphene also shows useful photothermal functions with NIR light absorption in the range of 700–1300 nm. Therefore, GO[112] and reduced graphene oxide (rGO)[113] have also been investigated as in vitro or in vivo photothermal therapy (PTT) agents for ablation of diseased cells. For example, Liu et al.[114] achieved NIR absorption and heat generation for in vivo PTT by combining nanosized graphene (<50 nm) and a PEG stabilizer with conjugation of NIRF dye, Cy7, to inhibit the quenching effect. Such rationally designed 2D graphene-based nanomaterials were then studied in vivo and their high accumulation in mice tumors after intravenous injection was observed. Importantly, with local NIR laser irradiation at tumor site, tumor-specific ablation was achieved without the observation of undesirable side effects, such as normal organ damages or weight loss, indicating the potential of graphene 2D materials in cancer therapy.\nExtending on the idea of minimal or noninvasive photothermal therapy based on the deep tissue penetrable NIR laser, other programmable 2D materials, such as PEGylated MoS2/Bi2S3 (MBP) composite nanosheets,[115] were designed by the bottom-up approach, which combines PTT mediated by MoS2 nanosheets, with Bi-related computed tomography (CT) imaging or radio therapy (RT). Incorporation of Bi into MoS2 nanosheets enhanced X-ray radiation and accelerated DNA breaking at tumor sites. In short, MBP composite nanosheets represent an attractive 2D material for tumor theragnostics, with photoacoustic or tomography guided tumor diagnosis, as well as RT or PTT."
    }, {
      "heading" : "4.2. Layered Nanomaterials for Nanodiagnostics at Molecular and Cellular Interfaces",
      "text" : "As an important layered nanomaterial, graphene shows interesting electronic properties and promising biosensing applications.[116] The key challenges for optimal biosensing applications lie in precise size and structure control of graphene foils, GO[117] and rGO,[118] as well as their interface.[119] Several groups have addressed these challenges by programming graphene for high detection efficiency towards mercury ions,[120] targeted genes,[121] and DNA.[122] More interestingly, graphene could also improve the performance of horseradish peroxidase, glucose oxidase, bilirubin oxidase, cytochrome c, and laccase in biomolecular sensing applications.[123]\nThe value of 2D graphene in nanodiagnostics at molecular interfaces also lies on its ability to form programmable FETs and bioFETs, which respond by changes in conductivity upon molecular detection.[124] For example, using electron beam\nlithography, graphene has been sculpted for nanomanipulation, nanochannels,[125,126] and nanopores,[126,127] which would allow DNA sequences to pass through. Graphene sequencers, or graphene nanodevices for DNA sequencing (Figure 9a), represent a creative idea for achieving reliable and fast DNA sequencing, due to physical absorption of DNA when passing through graphene nanopores, nanoribbons, or nanogaps.[128]\nIn addition, graphene that functions as a planar microelectrode has been utilized for the recording of extracellular electrophysiology, in a manner similar to conventional Si FETs. For example, the electrical activity detection of electrogenic cells was realized by using graphene-gated FET arrays.[129] In detail, graphene was utilized as a transistor for the culturing of cardiomyocyte-like cells (HL-1), by successfully detecting their action potentials. This indicates the promising application of 2D graphene in diagnosis at a cellular interface (Figure 9b). Furthermore, the propagation of cell signals could be clearly recorded by this graphene transistor array due to its high sensitivity. More recently, Fang et al.[130] demonstrated suspended graphene FET devices that could form close bioelectronics interfaces with cardiac cells and offer extracellular recordings 5 times more sensitive than devices using a substrate support. In comparison to 1D NW FETs, graphene FETs yielded higher averaged action potential signals, while NW FETs provided higher resolution signals consistent with their smaller device sizes. In short, graphene transistors surpassed cutting edge devices for bioelectronic applications, as demonstrated by their enhanced biosignals with reduced electronic noise.[21]\nIn addition to electrophysiology recordings, 2D nanomaterials could also broaden our understanding of cellular mechanical responses and physiology upon electrical stimulation. For instance, McAlpine et al.[109] exhibited that a 1 nm deflection at the membrane of neuronal cells could be detected by using piezoelectric PbZrxTi1−xO3 (PZT) nanoribbons (Figure 9c), with the application of 120 mV electrical excitation. Interestingly, this offered strong experimental evidence to support the theoretical calculation of cellular membrane depolarization induced by an applied voltage for constant membrane pressure. As an extension of the aforementioned method, flexible 2D PZT nanoribbon arrays were designed using a silicone elastomer support for successful mechanical quantification of respiration in a cow lung. This demonstrates the potential of 2D PZT nanoribbons as a minimally invasive electromechanical biosensing platform in living animals."
    }, {
      "heading" : "4.3. Layered Nanomaterials in Conformal Contact with Biological Tissues",
      "text" : "A recurring challenge at the nano–bio interface lies in a biomechanical mismatch between biological tissues and nanoimplants, which could be resolved by using soft layered nanomaterials, for example, soft planar neural implants with long-term biointegration in neural tissues.[131] Clinical trials revealed that the intracranial EEG or ECoG could be monitored in real time by placing an electrode on a rats cerebral cortex to map in vivo brain behavior. This has particular importance for epileptic foci positioning in neurosurgery. However, the development of electrode probes in mechanically heterogeneous neural\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (15 of 26)\ntissues has greatly been restricted by their traditional rigid interfaces, as insertion could lead to acute tissue responses. Fortunately, a soft 2D interface was recently designed by integrating a transparent silicone substrate, stretchable gold interconnects, and soft platinum-silicone electrodes. This had the purpose of mimicking the mechanical property of dura mater (Figure 10a) and can be used to achieve concurrent cortical stimulation and neural recording. Importantly, the spatial resolution of electrocorticograms recorded from this unique 2D interface allows the mapping of neuronal activation with response to each specific site of stimulation, with limited foreign body reaction.\nIn another example, Chen et al.[108] showed a highly stretchable and conductive electrode that exhibited stable resistance without the disturbance of any physical deformation, which was attractive for signal distortion elimination for neural signal recording (Figure 10b). This electrode was made of 2D sinusoidal Au nanobelts coated on a patterned tripod poly(dimethylsiloxane) (PDMS) surface, prestretched at maximum stretchability, and showed stable resistance even after a\n10 000 cyclic stretching process. Hence, the electrocorticogram of the rat was successfully recorded by this stretchable, soft, and stable electrode after surgical contact to its brain. Besides Au, 2D semiconductor carbon materials, such as graphene,[116] could also be assembled into flexible electrodes by using the universal tripod elastomeric substrate.\nWithin the last decade, electronics were programmed for flexibility and stretchability, allowing for conformation to nonplanar biological surfaces. Advances in epidermal electronic systems,[132] e.g., electronic devices that were conformally laminated and adhered onto the skin, exhibited great potentials in electrophysiological signal guided diagnosis (e.g., electromyograms and electrocardiograms) in a noninvasive manner. Typically, an epidermal electronic system comprises interconnected, ultrathin, conductive filaments, and an embedded sensor (e.g., strain and temperature sensors) in an all open mesh layout (Figure 10c). This can render the overall system with ultralow effective elastic moduli and large deformability.[133] More recently, the strategy of serpentine\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (16 of 26)\nfilaments found application in spatial mapping of the elastic biomechanical properties of soft biological tissues.[134] Additionally, flexible conformal devices could be applied to rigid biological surfaces, such as on the teeth. An example of this was a biointerfaced printable graphene nanosensor, fabricated through the self-assembly of antimicrobial peptides (Figure 10d). This nanosensor could detect a single bacteria cell due to its nanoscale nature and high sensitivity, and could be incorporated with a resonant coil for remote respiration monitoring and bacteria detection in saliva. This work represented a novel strategy of interfacing graphene nanosensors for versatile biochemical target detection.[135] Simply put, the thickness and planar topography of 2D layered nanomaterials have been intensively programmed to achieve flexible and stretchable devices, therefore allowing their conformal and intimate contact with the soft, curvilinear biological tissues. In these devices, such soft layered nanomaterials have enabled more friendly biointegration and have achieved higher fidelity of data retrieval; both of which are indispensable in developing reliable biointegrated devices. Furthermore, the emerging class of 2D hybrid nanomaterials with enhanced performance (e.g., graphene–CNTs, graphene– semiconductor nanomaterials, and graphene–metal nanomaterial hybrids) is also noteworthy, as this overcame the inherent\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (17 of 26)\ndisadvantages of 2D layered nanomaterials (i.e., easy aggregation, and poor solubility and processability) while leveraging their merits for biomedical applications by incorporating other functional nanomaterials into a scaffold made of layered nanomaterials.[136,137]"
    }, {
      "heading" : "5. 3D Nanomaterials/Nanosystems for Functional Biointegrated Devices",
      "text" : "The past decade has witnessed emerging 3D nanomaterials/nanosystems developed for biomedical applications: 1) 3D-architectured nanomaterials, such as vertically aligned SiNW arrays[20] or gold nanotip arrays;[138] 2) 3D hierarchical nanomaterials of low dimension (0D, 1D, 2D) nanomaterials, such as rGO foam;[139] and 3) the integrated assembly of low dimension nanomaterials. These 3D nanomaterials have opened new opportunities for biomedical devices, such as in implantable devices, minimally invasive devices, and wearable devices that are endowed with diagnosis function and controllable therapeutic capabilities. These are referred to as functional biointegrated devices, and are able to provide continuous diagnostic analysis and therapeutic administration. The emergence of these functional devices can be greatly accredited to the programming of nanomaterials.[123] For example, 2D nanomembranes (NMs)[19] have been extensively integrated into 3D integrated nanosystems in biomedical devices, since bulk rigid materials become deformable and flexible once thinned into NMs structures. When transferred to other flexible substrates, such as PDMS thin films, these NMs are capable of conformal contact with soft and curvilinear biological interfaces. The robust development of integrated 3D nanosystems has successfully interfaced a wide range of multifunctional, wearable, minimally invasive, and implantable biomedical devices with the human body, by addressing the challenges of mechanical disparity between rigid/planar devices and soft/curvilinear biological structures,[1] and incorporating therapeutic functional nanomaterials.\nThese integrated 3D nanosystems provide clinical signals[1] with improved ease of access and spatiotemporal precision, and are capable of controlled release of therapeutics. Biological systems provide many clinical cues, including physiological (e.g., pulse, temperature), mechanical (e.g., strain, pressure), thermal (e.g., thermal conductivity and distribution), electrophysiological (e.g., EEG, ECG), and biochemical (e.g., glucose, pH), signs. It is therefore advantageous for 3D nanomaterials that are loaded with pharmacological agents and used in drug delivery, to be activated by clinical cues (e.g., heat or electric signals), which are detected by the monitoring component of the nanomaterials."
    }, {
      "heading" : "5.1. 3D-Architectured and Hierarchical Nanomaterials for Spatial Nano–Bio Interactions",
      "text" : "A classic example of 3D-architectured nanomaterials is the vertically aligned Si nanopillar array (SiNP). A variety of 3D SiNP-based interfaces[20] have been fabricated for counting circulating tumor cells (CTCs), to evaluate cancer metastasis\nand monitor the efficacy of cancer therapies (Figure 11a). In one of the earlier works, 3D nanostructured substrates comprising an SiNP array that was modified with an epithelial cell adhesion molecule antibody (specifically recognized by tumor cells but not hematologic cells)[140] showed enhanced CTC isolation efficiency from whole blood samples. This is due to promoted local topographic interactions between the nanoscale cellular components and the SiNP array (Figure 11a, upper row). In a follow up work, an overlaid PDMS serpentine microfluidic chaotic mixer (turquoise) was integrated with a micropatterned SiNP array to improve capture efficiency by encouraging increased cell–substrate contact frequency.[141] More recently, fractal nano–bio interfaces based on 3D hierarchical nanomaterials[142] were developed to further boost CTC capture efficiency, based on a hierarchical assembled indium tin oxide (ITO) NW arrays with both horizontal and vertical NW branches (Figure 11a lower row). Compared to ITO NW arrays without branches, these 3D hierarchical NW arrays exhibited higher efficiency (89% vs 67%) in isolating CTC over a shorter capture time (35 vs 45 min), as a result of the nanotopographical interaction between cells and the 3D hierarchical NW arrays. This concept was also exhibited in the use of a hierarchical microporous and nanostructured 3D graphene composite foam to capture CTC.[139] The nanostructured surface could be programmed for thermoresponsiveness by introducing PNIPAAm onto SiNPs, in order to realize the reversible capture and release of CTC.[143] Besides CTC counting, 3D nanomaterials could also be programmed into flexible sensors; for example, molecularly modified AuNPs were utilized in a dynamic cross-reactive diagnostic sensing array for detecting volatile organic compounds in exhaled breath and noninvasive cancer diagnosis.[144]\nThe modulation of gene expression is a long-lasting target for regulating physiological functions and pathological causes; however, the precise delivery of nucleic acids to targeted tissues remains frustrated by poor transfection efficacy and scalability.[145] Vertical nanoneedles, which can offer physical access to cellular interior in a minimally invasive and nonspecific way, are capable of serving as a robust and powerful tool for delivering bioactive molecules (DNAs, RNAs, peptides, proteins, etc.) into various types of cells. As a general platform, it has been successfully applied to promote neuronal progenitor growth by administrating small molecules, interrupting gene transcription by introducing siRNAs, prevent apoptosis by delivering peptides, and even transport specific proteins to targeted organelles.[146] More recently, vertical arrays of biodegradable porous silicon nanoneedles exhibited excellent capability for the intracellular delivery of DNA and siRNA, with high efficiency (>90%) and minimal toxicity.[145] In addition to in vitro patterning of gene expression in both configurations (nN-B: cells over nanoneedles; nN-T: nanoneedles on top of cells), the porous nanoneedles are capable of triggering sustained neovascularization and increased blood perfusion in vivo, in the selected muscle, by transfecting the VEGF-165 gene (Figure 11b). In addition to delivering therapeutic agents, 3D vertical NW arrays have also been applied for intracellular electrophysiological recording,[93] cell and cellular mechanotransduction studies,[147,148] and label free cell sorting.[149]\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (18 of 26)\nThermotherapy constitutes one of the most common physiotherapies, particularly for treatment of joint injuries. While conventional devices for thermotherapy may cause discomfort due to their rigidity and heavy weight, the flexibility and stretchability of nanomaterials integrated devices can bypass this limitation. A nanocomposite of silver nanowires (AgNWs) and a thermoplastic elastomer SBS was utilized to construct a soft, thin, and stretchable heater.[150] To obtain a highly conductive and homogeneous nanocomposite, a ligand exchange reaction was conducted, followed by patterning of the nanocomposite into serpentine-mesh structures, as well as conformal lamination of the resultant heater on curvilinear joints (Figure 11c). The stretchable heater based on ligand exchanged AgNW nanocomposites provided a novel wearable system with effective heat transfer during motion for long term, continuous articular thermotherapy. Transdermal drug delivery (TDD) is an attractive alternative to oral delivery systems and intravenous administration, and has made pivotal contributions to the medication practice. Microneedles, a representative of third-generation TDD systems, target the stratum corneum and deliver drugs into the skin in a minimally invasive manner.[151] Recently, it has been shown that the combination of drug-laden NPs\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (19 of 26)\nAdv. Mater. 2017, 1605529\nwith micro needles can increase the versatility of conventional microneedles. By incorporating the nanoscale glucose-responsive insulin vesicles (GRVs) with the painless microneedles array, a “smart insulin patch” has been developed as a glucoseresponsive insulin delivery device.[152] GRVs are constructed through the self-assembly of hypoxia-sensitive hyaluronic acid (HS-HA) and the laden glucose oxidase (GOX) enzyme. The local hypoxic microenvironment triggers the vesicles dissociation and insulin release through the enzymatic oxidation of excessive blood glucose and subsequent reduction of HS-HA (Figure 11d). Compared to commonly used pH-sensitive formulations, this enzyme-based hypoxia trigger for insulin release can enable instantaneous response to minimize the risk of hypoglycemia.\nNanomaterial-hydrogel hybrids are hydrogel scaffolds embedded with 0D nanomaterials (gold,[153] iron oxide magnetic,[154] silica[155]), 1D nanomaterials (CNT[156]), and 2D nanomaterials (graphene[157]). They have also been developed to deliver drugs and genes[158] because hydrogels possess intrinsic advantages, such as appropriate mechanical properties, high porosity, and water content. Addition of nanomaterials into the hydrogel scaffold further imparts unique magnetic, electrical, catalytic, and optical properties on nanomaterial-hydrogel hybrid systems and enables remotely controllable actuation.[159] Decoration with appropriate nanomaterials can also render the hydrogel systems with stimuliresponsive properties. Given the influential role of temperature and pH condition in biological processes, temperature and pH responsive hydrogels are two extensively employed types of stimuli-sensitive hydrogels in biomedical applications.[160] Mechanical force-based stimuli could also provide another simple accessible cue for programmable transdermal drug delivery, as demonstrated by a wearable, strain-triggered drug delivery patch comprising a stretchable elastomer substrate, microgel depots filled with drug-containing NPs, and polymeric microneedles.[161]"
    }, {
      "heading" : "5.2. Integrative Nanoelectronic Devices for Nanodiagnostics and Nanotheragnostics",
      "text" : "The first FDA approved “digital pill” appeared in 2015; a milestone of progress in the technology of smart pills. A digital pill is a tablet with an embedded ingestible sensor that locates the pharmaceutical agents and transfers the feedback to another wearable sensor that records the medication patterns. Prior to this, researchers have long been enthusiastic about integrating electronic sensors with drug delivery systems, with the aims to retrieve information on medication patterns, as well as to actively monitor a patient’s physiological signals and deliver feedback therapy.[162]\nWearable biomedical devices that can continuously monitor biological signals, deliver feedback therapy, and collect and transfer data, are the next frontier in personalized healthcare and “precision medicine”.[158,163] These devices have significantly improved our knowledge of diseases, such as heart failure, diabetes, and Parkinson’s disease. However, the extensive adoption of these devices is frustrated by the absence of high performance sensors in intimate contact with soft and curvilinear tissues, reliable memory modules that store and transmit data during continuous long-term monitoring, and smart therapeutic modules capable of delivering advanced feedback therapy.[163] Fortunately, there have been recent advances in electronic devices that incorporate inorganic and organic nanomembranes and polymeric substrates in flexible and stretchable formats, which are in close contact with the skin as high signal-to-noise ratio sensors. Meanwhile, resistive random access memory (RRAM), developed from oxide nanomembranes, has emerged as a novel type of nonvolatile memory. A couple of multifunctional biointegrated devices have also been constructed through massive integration of 0D NPs, 2D NMs, and stretchable electronics on polymeric substrates. For example, a recent biointegrated system[163] with optimized multifunctionality of data storage, diagnosis, and drug delivery in the stretchable form, has been demonstrated (Figure 12a) to be\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (20 of 26)\nAdv. Mater. 2017, 1605529\neffective in monitoring motion-related neurological disorders and delivering therapy in response to diagnostic feedback. A silicon nanomembrane strain sensor was integrated to detect movement disorders, such as tremors, and AuNP RRAMs have been incorporated to store the monitored data. The corresponding feedback therapy triggers transdermal drug delivery from mesoporous silica NPs through thermal stimuli (e.g., a heater). In another example, an electrochemical device (Figure 12b), comprising a serpentine bilayer of gold mesh and gold-doped graphene, and thermoresponsive microneedles,[24] has provided an efficient electrochemical interface for sweat-based diabetes care and feedback therapy.\nIn addition, flexible and stretchable electronics can be extended to minimally invasive 3D electronics that can be integrated with biological constructs for continuous recording and modulation of their performance. Recently, the potential of such flexible electronics for targeted delivery to man-made and biological cavities has been demonstrated by Lieber et al.[164] Syringe-injectable electronics with 3D macroporous mesh structures that can be delivered through needles of diameters as small as 100 µm (Figure 13a) were used for in vivo multiplex neural recording in tight integration with the brain. This demonstrates the future of syringe injection as an effective approach for interpenetrating large volume, flexible electronics with 3D biological systems; thus, expanding the applications of flexible electronics. To optimize the integration of flexible electronics with brain tissue, Lieber et al.[165] have also introduced built-in strains for manipulating the local geometry of flexible electronics, in order to mitigate mechanical perturbation. Although current implantable endovascular devices for angioplasty can effectively achieve the instantaneous recovery of blood flow, inflammation and failure of long-term reendothelialization have frustrated their clinical applications, and suppression of these side effects greatly rely on in situ diagnosis and therapy. This challenge can be addressed by integration of high performance, flexible, bioresorbable electronics. An integrative bioresorbable electronic stent has been developed by recruiting a magnesium alloy stent decorated with ceria NPs, AuNR@MSN, rapamycin drugs, flow/temperature sensors, and a memory module (RRAM array).[166] The flow sensor monitors blood flow and the collected data is stored in the RRAM array for further diagnosis. Meanwhile, the combination of catalytic ROS scavenging (ceria NPs) and hyperthermia-induced drug release (AuNR@MSN) allows for advanced feedback therapy. In the event of hyperthermia, the feedback regulation of the temperature sensor would trigger localized drug release while providing thermotherapy (Figure 13b). In this way, this suite of sensors and actuators can be endowed with multifunctionality, including flow monitoring, temperature measuring, data recording, wireless power/data transmission, inflammation treatment, responsive drug release, and hyperthermia therapy, as well as provide mechanical and structural support. We believe the future of such smart theragnostic platforms lie in the integration of sensors (biomechanical and biochemical sensing), data storage modules, responsive therapeutic elements, as well as wireless power and data communication in bioresorbable constructs.\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (21 of 26)\nAdv. Mater. 2017, 1605529"
    }, {
      "heading" : "5.3. Bionic Devices Redefining Synthetic Biology",
      "text" : "Developing 3D synthetic biomaterials with structural and bioactive functions is crucial in such fields as synthetic biology[167] and regenerative medicine.[168] 3D biomaterials with hierarchical biophysical properties[29] and spatiotemporal biochemical stimulants that recapitulate extracellular matrix (ECM), represent a pivotal pursuit towards understanding the pharmacological effects on cells within synthetic systems, thereby offering high-fidelity guidance for in vivo disease treatment. However, the challenge lies in limited access to the spatiotemporal interaction of these scaffolds with artificial microenvironments. The incorporation of multifunctional nanoelectronic networks into biomimetic and biological elements, which constructs the conceptual “cyborg tissues”, has been proven to effectively address this challenge. A hybrid scaffold was developed by interweaving 3D macroporous and flexible nanowire nanoelectronic scaffolds (nanoES) with biocompatible biomaterials,[168] for the 3D culture of various cells (Figure 14a). The resulting 3D-nanoESbased synthetic tissue exhibited robust sensory capability, with regards to the responses of the constructed models to drug stimulus and pH changes, through monitoring of the local electrical activity in real time. In a follow-up work, researchers further enable synchronized contraction of cardiomyocytes upon controllable electrical stimulation through electroactive polymers, which was equally capable of monitoring the performance of synthetic tissue.[169] Recently, Kim et al. have demonstrated the concept of “muscle-on-a-chip”, on the basis of ultrathin stretchable nanomembrane sensors and graphene nanoribbon cell aligners. The soft integrated muscle-on-a-chip is capable of physiological monitoring of aligned cells, high yield transfer printing, and delivering cell ensembles for cell therapy.[170]\nMeanwhile, other efforts are made to bridge the functional gap between prosthetic and human skin, by replicating the sensory capabilities of neural circuits underlying skin based mechanoreceptors and thermoreceptors.[171,172] A stretchable prosthetic skin (Figure 14b) has been developed by incorporating ultrathin silicon nanoribbon strain, pressure and temperature sensor arrays, humidity sensors, electroresistive heaters, stretchable multiple nanowire based electrodes for nerve stimulation, and ceria NPs for inflammation control. Apart from mimicking mechanoreceptors, skin moisture sensing and body temperature control were also respectively recapitulated by the integrated stretchable humidity sensors and electroresistive heaters. The tailorable geometry and intrinsic stretchability of the prosthetic skin provide high spatiotemporal sensitivity and mechanical stability, thereby significantly augmenting the sensory capabilities of the prosthetic skin, even under highly variable conditions. More interestingly, the prosthetic skin is connected to the nerve cord via the conformally attached ultrathin stretchable nanowire-based electrodes, which can transmit externally detected signals from the body to stimulate nerves. In this process, efficient electrical signal transmission was facilitated by the high conductivity and large surface area of Pt NWs on the electrodes. Meanwhile, ceria NPs were also incorporated to suppress inflammation induced by reactive oxygen.\nBriefly, 3D nanomaterials and nanosystems have been extensively incorporated in the applications of 3D therapeutic\nand diagnostic devices, integrative nanoelectronic devices, and bionic devices. This is realized by programming the precise spatial interaction with bioentities at the nano–bio interfaces, as well as the orchestrated integration of functional modules based on nanomaterials of lower dimensional scales. As a result, numerous wearable, minimally invasive, and implantable devices have been developed for nanotheragnostics and regenerative nanomedicine."
    }, {
      "heading" : "6. Conclusion and Perspectives",
      "text" : "In summary, recent advances at the interface between nanotechnology and bioentities, also known as the nano–bio interface, have tremendously shaped the landscape of clinical diagnosis and therapeutic intervention. Diagnostic probes and therapeutic tools that utilize nanomaterials have proven themselves to be capable of the rigorous demands of the clinical laboratory, with respect to sensitivity and cost-effectiveness.[173] Multifunctional NPs have significant advantages over conventional imaging probes and therapeutic agents based on small molecules, and are therefore indispensable in multimodal imaging and theragnostics, as well as targeted therapeutics delivery in current biomedical research. Meanwhile, 1D and 2D nanomaterials can be utilized for electrical recording[174] and data transmission, on top of the aforementioned applications.[175] Lastly, 3D integrated nanosystems exhibit great promise toward the development of functional implantable, minimally invasive, and wearable devices,[1,23] as well as prosthetic tissues and cyborg tissues.[105,169] However, the assembly of nanomaterials on different dimension scales in biointegrated devices is still limited. Currently, only thermo- or electroactivated biointegrated devices have been successfully fabricated with therapeutic NPs as the responsive and drug delivery elements.[24,166] Incorporation of more advanced multifunctional NPs (e.g., sequential or synergistic theragnostic NPs) will allow even smarter biointegrated devices.\nIn our opinion, the progress of nano–bio interfaces reflects a reciprocal development of biomedical nanomaterials and biomedicine. Here, we emphasize how the design of nanomaterials of various dimension scales has been promising in delivering effective diagnostic, therapeutic, theragnostic, and regenerative systems/devices. Specifically, the respective strategies of programming nano–bio interfaces, by tailoring nanomaterials at different dimensional scales, have been illustrated in detail, and constitute unique functional modules in biointegrated devices. Nonetheless, it is important to note that nanomaterials have also been designed to study administered therapeutic intervention and pathological or physiological patterns, in order to advance biomedical knowledge and lead to further improvement of nano–bio interfaces. With a more comprehensive knowledge of the mechanisms behind the aforementioned processes, we can make more informed designs for maximizing the potential of nanotechnology in biomedicine, while bypassing their side effects.[176,177] Most importantly, translating smart nanomaterials from prototype demonstrations into (pre)clinical applications ought to be the core subject in future research.\nNowadays, the concept of precision medicine has been advocated, in which each patient needs optimized and personalized\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (22 of 26)\nAdv. Mater. 2017, 1605529\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (23 of 26)\nAdv. Mater. 2017, 1605529\ntherapy that takes into account individual variations in genetic and environmental factors, as well as disease conditions. The heterogeneity of diseases amongst patients is widely accepted by biomedical researchers and, increasingly, the idea of “one size fits all” biomaterials has been abandoned in favor of personalized medical intervention to improve (pre)clinical efficacy. In the complicated in vivo microenvironment, diversity exists in cell lineages, tissue specific cellular transmembrane receptors, tissue structure, and mechanical properties[9,31,178] across different tissue sites and local pathology.[179] These complex microenvironmental variables may alter the properties of the introduced nanomaterials and affect their in vivo performance. In order to fulfill this, detailed information regarding the heterogeneity of disease and individual patients would be required. Recent advances in nanosystem design, accompanied by thorough investigations of tissue-material interactions at the nano–bio interfaces, offer promise to personalized medicine, in which nanomaterials are programmed according to the specific tissue microenvironment and disease patterns. In noninvasive diagnosis, nanosystem-based in vivo monitoring techniques are potent in visualizing disease conditions and therapeutic efficacy of the delivered medical intervention at targeted sites. Herein, so-called personalized nanomedicine is potent in overcoming the hurdles of conventional diagnostics and therapeutics. In line with this, it becomes necessary to thoroughly investigate tissue microenvironment and to optimize the design of nano– bio interfaces for the implementation of nanosystems. This practice would not only enable predictable nanosystem performance, but also boost their clinical efficacy."
    }, {
      "heading" : "Acknowledgements",
      "text" : "X.C. acknowledges financial support from NTU-Northwestern Institute for Nanomedicine, Singapore. Y.-L.W. also gives thanks for financial supports from the Natural Science Foundation of China (21303145) and the Natural Science Foundation of Fujian Province of China (2014J01063).\nKeywords biointegrated devices, nanomedicine, nano–bio interfaces, programmable nanomaterials\nReceived: October 13, 2016 Revised: January 7, 2017\nPublished online:\n[1] S. Choi, H. Lee, R. Ghaffari, T. Hyeon, D. H. Kim, Adv. Mater. 2016, 28, 4203. [2] A. E. Nel, L. Madler, D. Velegol, T. Xia, E. M. Hoek, P. Somasundaran, F. Klaessig, V. Castranova, M. Thompson, Nat. Mater. 2009, 8, 543. [3] Y. L. Wu, N. Putcha, K. W. Ng, D. T. Leong, C. T. Lim, S. C. Loo, X. Chen, Acc. Chem. Res. 2013, 46, 782. [4] S. Prakash, M. Malhotra, W. Shao, C. Tomaro-Duchesneau, S. Abbasi, Adv. Drug Delivery Rev. 2011, 63, 1340. [5] T. Sun, G. Qing, Adv. Healthcare Mater. 2011, 23, H57. [6] G. Y. Tonga, K. Saha, V. M. Rotello, Adv. Mater. 2014, 26, 359.\n[7] T. E. Mallouk, P. Yang, J. Am. Chem. Soc. 2009, 131, 7937. [8] S. Mura, J. Nicolas, P. Couvreur, Nat. Mater. 2013, 12, 991. [9] U. G. Wegst, H. Bai, E. Saiz, A. P. Tomsia, R. O. Ritchie,\nNat. Mater. 2015, 14, 23. [10] M. Schvartzman, M. Palma, J. Sable, J. Abramson, X. Hu,\nM. P. Sheetz, S. J. Wind, Nano Lett. 2011, 11, 1306. [11] Y. Sun, Q. Jallerat, J. M. Szymanski, A. W. Feinberg, Nat. Methods\n2015, 12, 134. [12] R. Hao, R. Xing, Z. Xu, Y. Hou, S. Gao, S. Sun, Adv. Mater. 2010,\n22, 2729. [13] T. Lammers, S. Aime, W. E. Hennink, G. Storm, F. Kiessling,\nAcc. Chem. Res. 2011, 44, 1029. [14] D. E. Lee, H. Koo, I. C. Sun, J. H. Ryu, K. Kim, I. C. Kwon, Chem.\nSoc. Rev. 2012, 41, 2656. [15] W. Yang, P. Thordarson, J. J. Gooding, S. P. Ringer, F. Braet,\nNanotechnology 2007, 18, 412001. [16] N. P. Dasgupta, J. Sun, C. Liu, S. Brittman, S. C. Andrews, J. Lim,\nH. Gao, R. Yan, P. Yang, Adv. Mater. 2014, 26, 2137. [17] Y. Chen, C. Tan, H. Zhang, L. Wang, Chem. Soc. Rev. 2015, 44,\n2681. [18] Y. Zhu, S. Murali, W. Cai, X. Li, J. W. Suk, J. R. Potts, R. S. Ruoff,\nAdv. Mater. 2010, 22, 3906. [19] J. A. Rogers, M. G. Lagally, R. G. Nuzzo, Nature 2011, 477, 45. [20] X. Liu, S. Wang, Chem. Soc. Rev. 2014, 43, 2385. [21] A. Zhang, C. M. Lieber, Chem. Rev. 2016, 116, 215. [22] L. Yang, Y. Li, Y. Fang, Adv. Mater. 2013, 25, 3881. [23] B. Zhu, H. Wang, W. R. Leow, Y. Cai, X. J. Loh, M. Y. Han, X. Chen,\nAdv. Mater. 2015, 28, 4250. [24] H. Lee, T. K. Choi, Y. B. Lee, H. R. Cho, R. Ghaffari, L. Wang,\nH. J. Choi, T. D. Chung, N. Lu, T. Hyeon, S. H. Choi, D. H. Kim, Nat. Nanotechnol. 2016, 11, 566. [25] D. B. Pacardo, F. S. Ligler, Z. Gu, Nanoscale 2015, 7, 3381. [26] T. Dvir, B. P. Timko, D. S. Kohane, R. Langer, Nat. Nanotechnol.\n2011, 6, 13. [27] Y. Gao, J. Lim, S.-H. Teoh, C. Xu, Chem. Soc. Rev. 2015, 44, 6306. [28] C. Y. Tay, P. Cai, M. I. Setyawati, W. Fang, L. P. Tan, C. H. Hong,\nX. Chen, D. T. Leong, Nano Lett. 2014, 14, 83. [29] P. Cai, M. Layani, W. R. Leow, S. Amini, Z. Liu, D. Qi, B. Hu,\nY. L. Wu, A. Miserez, S. Magdassi, X. Chen, Adv. Mater. 2016, 28, 3102. [30] B. Trappmann, J. E. Gautrot, J. T. Connelly, D. G. T. Strange, Y. Li, M. L. Oyen, M. A. Stuart, H. Boehm, B. Li, V. Vogel, J. P. Spatz, F. M. Watt, W. T. S. Huck, Nat. Mater. 2012, 11, 642. [31] C. Tay, Y.-L. Wu, P. Cai, N. Tan, S. S. Venkatraman, X. Chen, L. Tan, NPG Asia Mater. 2015, 7, e199. [32] C. R. Lam, C. Tan, Z. Teo, C. Y. Tay, T. Phua, Y. L. Wu, P. Q. Cai, L. P. Tan, X. Chen, P. Zhu, N. S. Tan, Cell Death Dis. 2013, 4, e848. [33] J. Park, D. H. Kim, H. N. Kim, C. J. Wang, M. K. Kwak, E. Hur, K. Y. Suh, S. S. An, A. Levchenko, Nat. Mater. 2016, 15, 792. [34] I. C. Sun, D. K. Eun, H. Koo, C. Y. Ko, H. S. Kim, D. K. Yi, K. Choi, I. C. Kwon, K. Kim, C. H. Ahn, Angew. Chem., Int. Ed. 2011, 50, 9348. [35] R. Torres Martin de Rosales, R. Tavare, R. L. Paul, M. Jauregui-Osoro, A. Protti, A. Glaria, G. Varma, I. Szanda, P. J. Blower, Angew. Chem., Int. Ed. 2011, 50, 5509. [36] J. S. Choi, J. C. Park, H. Nah, S. Woo, J. Oh, K. M. Kim, G. J. Cheon, Y. Chang, J. Yoo, J. Cheon, Angew. Chem., Int. Ed. 2008, 47, 6259. [37] J. Xie, K. Chen, J. Huang, S. Lee, J. Wang, J. Gao, X. Li, X. Chen, Biomaterials 2010, 31, 3016. [38] E. C. Dreaden, A. M. Alkilany, X. Huang, C. J. Murphy, M. A. El-Sayed, Chem. Soc. Rev. 2012, 41, 2740. [39] D. S. Seferos, D. A. Giljohann, H. D. Hill, A. E. Prigodich, C. A. Mirkin, J. Am. Chem. Soc. 2007, 129, 15477.\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (24 of 26)\nAdv. Mater. 2017, 1605529\n[40] A. J. Shuhendler, K. Pu, L. Cui, J. P. Uetrecht, J. Rao, Nat. Biotechnol. 2014, 32, 373. [41] K. Pu, A. J. Shuhendler, J. Rao, Angew. Chem., Int. Ed. 2013, 52, 10325. [42] L. Xiong, A. J. Shuhendler, J. Rao, Nat. Commun. 2012, 3, 1193. [43] P. M. Kosaka, V. Pini, J. J. Ruz, R. A. da Silva, M. U. Gonzalez,\nD. Ramos, M. Calleja, J. Tamayo, Nat. Nanotechnol. 2014, 9, 1047. [44] S. Nagrath, L. V. Sequist, S. Maheswaran, D. W. Bell, D. Irimia,\nL. Ulkus, M. R. Smith, E. L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U. J. Balis, R. G. Tompkins, D. A. Haber, M. Toner, Nature 2007, 450, 1235. [45] S. L. Stott, C. H. Hsu, D. I. Tsukrov, M. Yu, D. T. Miyamoto, B. A. Waltman, S. M. Rothenberg, A. M. Shah, M. E. Smas, G. K. Korir, F. P. Floyd Jr., A. J. Gilman, J. B. Lord, D. Winokur, S. Springer, D. Irimia, S. Nagrath, L. V. Sequist, R. J. Lee, K. J. Isselbacher, S. Maheswaran, D. A. Haber, M. Toner, Proc. Natl. Acad. Sci. USA 2010, 107, 18392. [46] F. Brinkmann, M. Hirtz, A. Haller, T. M. Gorges, M. J. Vellekoop, S. Riethdorf, V. Muller, K. Pantel, H. Fuchs, Sci. Rep. 2015, 5, 15342. [47] J. Das, I. Ivanov, E. H. Sargent, S. O. Kelley, J. Am. Chem. Soc. 2016, 138, 11009. [48] E. Ozkumur, A. M. Shah, J. C. Ciciliano, B. L. Emmink, D. T. Miyamoto, E. Brachtel, M. Yu, P. I. Chen, B. Morgan, J. Trautwein, A. Kimura, S. Sengupta, S. L. Stott, N. M. Karabacak, T. A. Barber, J. R. Walsh, K. Smith, P. S. Spuhler, J. P. Sullivan, R. J. Lee, D. T. Ting, X. Luo, A. T. Shaw, A. Bardia, L. V. Sequist, D. N. Louis, S. Maheswaran, R. Kapur, D. A. Haber, M. Toner, Sci. Transl. Med. 2013, 5, 179ra47. [49] B. J. Green, T. Saberi Safaei, A. Mepham, M. Labib, R. M. Mohamadi, S. O. Kelley, Angew. Chem., Int. Ed. 2016, 55, 1252. [50] W. Li, E. Reategui, M. H. Park, S. Castleberry, J. Z. Deng, B. Hsu, S. Mayner, A. E. Jensen, L. V. Sequist, S. Maheswaran, D. A. Haber, M. Toner, S. L. Stott, P. T. Hammond, Biomaterials 2015, 65, 93. [51] Y.-Q. Li, B. K. Chandran, C. T. Lim, X. Chen, Adv. Sci. 2015, 2, 1500118. [52] N. Sun, M. Liu, J. Wang, Z. Wang, X. Li, B. Jiang, R. Pei, Small 2016, 12, 5090. [53] G. A. Kwong, G. von Maltzahn, G. Murugappan, O. Abudayyeh, S. Mo, I. A. Papayannopoulos, D. Y. Sverdlov, S. B. Liu, A. D. Warren, Y. Popov, D. Schuppan, S. N. Bhatia, Nat. Biotechnol. 2013, 31, 63. [54] D. Cai, L. Ren, H. Zhao, C. Xu, L. Zhang, Y. Yu, H. Wang, Y. Lan, M. F. Roberts, J. H. Chuang, M. J. Naughton, Z. Ren, T. C. Chiles, Nat. Nanotechnol. 2010, 5, 597. [55] H. Yang, Pharm. Res. 2010, 27, 1759. [56] S. C. Baetke, T. Lammers, F. Kiessling, Br. J. Radiol. 2015, 88,\n20150207. [57] F. Tang, L. Li, D. Chen, Adv. Mater. 2012, 24, 1504. [58] J. Li, C. Fan, H. Pei, J. Shi, Q. Huang, Adv. Mater. 2013, 25, 4386. [59] B. Q. Spring, R. Bryan Sears, L. Z. Zheng, Z. Mai, R. Watanabe,\nM. E. Sherwood, D. A. Schoenfeld, B. W. Pogue, S. P. Pereira, E. Villa, T. Hasan, Nat. Nanotechnol. 2016, 11, 378. [60] E. Y. Lukianova-Hleb, X. Ren, R. R. Sawant, X. Wu, V. P. Torchilin, D. O. Lapotko, Nat. Med. 2014, 20, 778. [61] E. Y. Lukianova-Hleb, Y. S. Kim, I. Belatsarkouski, A. M. Gillenwater, B. E. O’Neill, D. O. Lapotko, Nat. Nanotechnol. 2016, 11, 525. [62] J. Z. Du, X. J. Du, C. Q. Mao, J. Wang, J. Am. Chem. Soc. 2011, 133, 17560. [63] L. Pan, J. Liu, Q. He, J. Shi, Adv. Mater. 2014, 26, 6742. [64] Y. Yuan, Z. Wang, P. Cai, J. Liu, L. D. Liao, M. Hong, X. Chen,\nN. Thakor, B. Liu, Nanoscale 2015, 7, 3067. [65] S. M. Janib, A. S. Moses, J. A. MacKay, Adv. Drug Delivery Rev.\n2010, 62, 1052. [66] T. Wang, L. Zhang, Z. Su, C. Wang, Y. Liao, Q. Fu, ACS Appl. Mater.\nInterfaces 2011, 3, 2479.\n[67] J. E. Lee, N. Lee, H. Kim, J. Kim, S. H. Choi, J. H. Kim, T. Kim, I. C. Song, S. P. Park, W. K. Moon, T. Hyeon, J. Am. Chem. Soc. 2010, 132, 552. [68] S. J. Lee, H. Koo, H. Jeong, M. S. Huh, Y. Choi, S. Y. Jeong, Y. Byun, K. Choi, K. Kim, I. C. Kwon, J. Controlled Release 2011, 152, 21. [69] C. L. Peng, Y. H. Shih, P. C. Lee, T. M. Hsieh, T. Y. Luo, M. J. Shieh, ACS Nano 2011, 5, 5594. [70] B. L. Viglianti, S. A. Abraham, C. R. Michelich, P. S. Yarmolenko, J. R. MacFall, M. B. Bally, M. W. Dewhirst, Magn. Reson. Med. 2004, 51, 1153. [71] J. Liu, J. Bu, W. Bu, S. Zhang, L. Pan, W. Fan, F. Chen, L. Zhou, W. Peng, K. Zhao, J. Du, J. Shi, Angew. Chem., Int. Ed. 2014, 53, 4551. [72] Z. Fan, L. Sun, Y. Huang, Y. Wang, M. Zhang, Nat. Nanotechnol. 2016, 11, 388. [73] Y. Yuan, C.-J. Zhang, R. T. K. Kwok, S. Xu, R. Zhang, J. Wu, B. Z. Tang, B. Liu, Adv. Funct. Mater. 2015, 25, 6586. [74] S.-Y. Li, L.-H. Liu, L. Rong, W.-X. Qiu, H.-Z. Jia, B. Li, F. Li, X.-Z. Zhang, Adv. Funct. Mater. 2015, 25, 7317. [75] Y. Min, J. Li, F. Liu, E. K. Yeow, B. Xing, Angew. Chem., Int. Ed. 2014, 53, 1012. [76] L. Zhang, J. Lei, F. Ma, P. Ling, J. Liu, H. Ju, Chem. Commun. 2015, 51, 10831. [77] S. Rafii, D. Lyden, Nat. Med. 2003, 9, 702. [78] M. Edmundson, N. T. Thanh, B. Song, Theranostics 2013, 3, 573. [79] G. R. Jin, D. Mao, P. Q. Cai, R. R. Liu, N. Tomczak, J. Liu,\nX. D. Chen, D. L. Kong, D. Ding, B. Liu, K. Li, Adv. Funct. Mater. 2015, 25, 4263. [80] M. S. Mannoor, Z. Jiang, T. James, Y. L. Kong, K. A. Malatesta, W. O. Soboyejo, N. Verma, D. H. Gracias, M. C. McAlpine, Nano Lett. 2013, 13, 2634. [81] N. Desai, AAPS J. 2012, 14, 282. [82] J. H. Park, G. von Maltzahn, L. L. Ong, A. Centrone, T. A. Hatton,\nE. Ruoslahti, S. N. Bhatia, M. J. Sailor, Adv. Mater. 2010, 22, 880. [83] M. K. Gupta, F. Meng, B. N. Johnson, Y. L. Kong, L. Tian,\nY. W. Yeh, N. Masters, S. Singamaneni, M. C. McAlpine, Nano. Lett. 2015, 15, 5321. [84] Z. Liu, W. Cai, L. He, N. Nakayama, K. Chen, X. Sun, X. Chen, H. Dai, Nat. Nanotechnol. 2007, 2, 47. [85] A. De la Zerda, C. Zavaleta, S. Keren, S. Vaithilingam, S. Bodapati, Z. Liu, J. Levi, B. R. Smith, T. J. Ma, O. Oralkan, Z. Cheng, X. Chen, H. Dai, B. T. Khuri-Yakub, S. S. Gambhir, Nat. Nanotechnol. 2008, 3, 557. [86] N. W. S. Kam, M. O’Connell, J. A. Wisdom, H. J. Dai, Proc. Natl. Acad. Sci. USA 2005, 102, 11600. [87] K. Kostarelos, L. Lacerda, G. Pastorin, W. Wu, S. Wieckowski, J. Luangsivilay, S. Godefroy, D. Pantarotto, J. P. Briand, S. Muller, M. Prato, A. Bianco, Nat. Nanotechnol. 2007, 2, 108. [88] G. Hong, S. Diao, A. L. Antaris, H. Dai, Chem. Rev. 2015, 115, 10816. [89] N. W. S. Kam, H. J. Dai, J. Am. Chem. Soc. 2005, 127, 6021. [90] N. W. Kam, Z. Liu, H. Dai, Angew. Chem., Int. Ed. 2006, 45, 577. [91] Z. Liu, M. Winters, M. Holodniy, H. Dai, Angew. Chem., Int. Ed.\n2007, 46, 2023. [92] A. A. Bhirde, V. Patel, J. Gavard, G. Zhang, A. A. Sousa,\nA. Masedunskas, R. D. Leapman, R. Weigert, J. S. Gutkind, J. F. Rusling, ACS Nano 2009, 3, 307. [93] J. T. Robinson, M. Jorgolli, A. K. Shalek, M. H. Yoon, R. S. Gertner, H. Park, Nat. Nanotechnol. 2012, 7, 180. [94] A. I. Hochbaum, D. Gargas, Y. J. Hwang, P. Yang, Nano Lett. 2009, 9, 3550. [95] Z. Huang, H. Fang, J. Zhu, Adv. Mater. 2007, 19, 744. [96] Z. Huang, N. Geyer, P. Werner, J. de Boor, U. Gosele, Adv. Mater.\n2011, 23, 285. [97] Y. Z. Long, M. Yu, B. Sun, C. Z. Gu, Z. Fan, Chem. Soc. Rev. 2012,\n41, 4560.\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (25 of 26)\nAdv. Mater. 2017, 1605529\n[98] Y. Cui, Q. Wei, H. Park, C. M. Lieber, Science 2001, 293, 1289. [99] G. Zheng, F. Patolsky, Y. Cui, W. U. Wang, C. M. Lieber, Nat.\nBiotechnol. 2005, 23, 1294. [100] F. Patolsky, B. P. Timko, G. Yu, Y. Fang, A. B. Greytak, G. Zheng,\nC. M. Lieber, Science 2006, 313, 1100. [101] Y. T. Li, S. H. Zhang, L. Wang, R. R. Xiao, W. Liu, X. W. Zhang,\nZ. Zhou, C. Amatore, W. H. Huang, Angew. Chem., Int. Ed. 2014, 53, 12456. [102] Y. L. Liu, Z. H. Jin, Y. H. Liu, X. B. Hu, Y. Qin, J. Q. Xu, C. F. Fan, W. H. Huang, Angew. Chem., Int. Ed. 2016, 55, 4537. [103] H. Hu, Y. Ni, V. Montana, R. C. Haddon, V. Parpura, Nano Lett. 2004, 4, 507. [104] M. K. Gheith, V. A. Sinani, J. P. Wicksted, R. L. Matts, N. A. Kotov, Adv. Mater. 2005, 17, 2663. [105] M. K. Gheith, T. C. Pappas, A. V. Liopo, V. A. Sinani, B. S. Shim, M. Motamedi, J. P. Wicksted, N. A. Kotov, Adv. Mater. 2006, 18, 2975. [106] J. N. Coleman, M. Lotya, A. O’Neill, S. D. Bergin, P. J. King, U. Khan, K. Young, A. Gaucher, S. De, R. J. Smith, I. V. Shvets, S. K. Arora, G. Stanton, H. Y. Kim, K. Lee, G. T. Kim, G. S. Duesberg, T. Hallam, J. J. Boland, J. J. Wang, J. F. Donegan, J. C. Grunlan, G. Moriarty, A. Shmeliov, R. J. Nicholls, J. M. Perkins, E. M. Grieveson, K. Theuwissen, D. W. McComb, P. D. Nellist, V. Nicolosi, Science 2011, 331, 568. [107] J. Viventi, D. H. Kim, L. Vigeland, E. S. Frechette, J. A. Blanco, Y. S. Kim, A. E. Avrin, V. R. Tiruvadi, S. W. Hwang, A. C. Vanleer, D. F. Wulsin, K. Davis, C. E. Gelber, L. Palmer, J. Van der Spiegel, J. Wu, J. Xiao, Y. Huang, D. Contreras, J. A. Rogers, B. Litt, Nat. Neurosci. 2011, 14, 1599. [108] D. Qi, Z. Liu, M. Yu, Y. Liu, Y. Tang, J. Lv, Y. Li, J. Wei, B. Liedberg, Z. Yu, X. Chen, Adv. Mater. 2015, 27, 3145. [109] T. D. Nguyen, N. Deshmukh, J. M. Nagarah, T. Kramer, P. K. Purohit, M. J. Berry, M. C. McAlpine, Nat. Nanotechnol. 2012, 7, 587. [110] X. Sun, Z. Liu, K. Welsher, J. T. Robinson, A. Goodwin, S. Zaric, H. Dai, Nano Res. 2008, 1, 203. [111] T. Jiang, W. Sun, Q. Zhu, N. A. Burns, S. A. Khan, R. Mo, Z. Gu, Adv. Mater. 2015, 27, 1021. [112] M. Li, X. Yang, J. Ren, K. Qu, X. Qu, Adv. Mater. 2012, 24, 1722. [113] J. T. Robinson, S. M. Tabakman, Y. Liang, H. Wang,\nH. S. Casalongue, D. Vinh, H. Dai, J. Am. Chem. Soc. 2011, 133, 6825. [114] K. Yang, S. Zhang, G. Zhang, X. Sun, S. T. Lee, Z. Liu, Nano Lett. 2010, 10, 3318. [115] S. Wang, X. Li, Y. Chen, X. Cai, H. Yao, W. Gao, Y. Zheng, X. An, J. Shi, H. Chen, Adv. Mater. 2015, 27, 2775. [116] D. Qi, Z. Liu, Y. Liu, W. R. Leow, B. Zhu, H. Yang, J. Yu, W. Wang, H. Wang, S. Yin, X. Chen, Adv. Mater. 2015, 27, 5559. [117] A. L. Higginbotham, D. V. Kosynkin, A. Sinitskii, Z. Sun, J. M. Tour, ACS Nano 2010, 4, 2059. [118] C. K. Chua, M. Pumera, Chem. Soc. Rev. 2014, 43, 291. [119] A. Hirsch, J. M. Englert, F. Hauke, Acc. Chem. Res. 2013,\n46, 87. [120] T. Zhang, Z. Cheng, Y. Wang, Z. Li, C. Wang, Y. Li, Y. Fang,\nNano Lett. 2010, 10, 4738. [121] H. Bao, Y. Pan, Y. Ping, N. G. Sahoo, T. Wu, L. Li, J. Li, L. H. Gan,\nSmall 2011, 7, 1569. [122] O. Akhavan, E. Ghaderi, R. Rahighi, ACS Nano 2012, 6,\n2904. [123] O. N. Oliveira Jr., R. M. Iost, J. R. Siqueira Jr., F. N. Crespilho,\nL. Caseli, ACS Appl. Mater. Interfaces 2014, 6, 14745. [124] K. Balasubramanian, K. Kern, Adv. Mater. 2014, 26, 1154. [125] S. K. Min, W. Y. Kim, Y. Cho, K. S. Kim, Nat. Nanotechnol. 2011, 6,\n162. [126] N. A. Bell, U. F. Keyser, Nat. Nanotechnol. 2016, 11, 645.\n[127] F. Traversi, C. Raillon, S. M. Benameur, K. Liu, S. Khlybov, M. Tosun, D. Krasnozhon, A. Kis, A. Radenovic, Nat. Nanotechnol. 2013, 8, 939. [128] S. J. Heerema, C. Dekker, Nat. Nanotechnol. 2016, 11, 127. [129] L. H. Hess, M. Jansen, V. Maybeck, M. V. Hauf, M. Seifert,\nM. Stutzmann, I. D. Sharp, A. Offenhausser, J. A. Garrido, Adv. Mater. 2011, 23, 5045. [130] Z. Cheng, J. Hou, Q. Zhou, T. Li, H. Li, L. Yang, K. Jiang, C. Wang, Y. Li, Y. Fang, Nano Lett. 2013, 13, 2902. [131] I. R. Minev, P. Musienko, A. Hirsch, Q. Barraud, N. Wenger, E. Moraud, J. Gandar, M. Capogrosso, T. Milekovic, L. Asboth, R. Torres, N. Vachicouras, Q. Liu, N. Pavlova, S. Duis, A. Larmagnac, J. Vörös, S. Micera, Z. Suo, G. Courtine, S. P. Lacour, Science 2015, 347, 159. [132] D. H. Kim, N. Lu, R. Ma, Y. S. Kim, R. H. Kim, S. Wang, J. Wu, S. M. Won, H. Tao, A. Islam, K. J. Yu, T. I. Kim, R. Chowdhury, M. Ying, L. Xu, M. Li, H. J. Chung, H. Keum, M. McCormick, P. Liu, Y. W. Zhang, F. G. Omenetto, Y. Huang, T. Coleman, J. A. Rogers, Science 2011, 333, 838. [133] W. H. Yeo, Y. S. Kim, J. Lee, A. Ameen, L. Shi, M. Li, S. Wang, R. Ma, S. H. Jin, Z. Kang, Y. Huang, J. A. Rogers, Adv. Mater. 2013, 25, 2773. [134] C. Dagdeviren, Y. Shi, P. Joe, R. Ghaffari, G. Balooch, K. Usgaonkar, O. Gur, P. L. Tran, J. R. Crosby, M. Meyer, Y. Su, R. Chad Webb, A. S. Tedesco, M. J. Slepian, Y. Huang, J. A. Rogers, Nat. Mater. 2015, 14, 728. [135] M. S. Mannoor, H. Tao, J. D. Clayton, A. Sengupta, D. L. Kaplan, R. R. Naik, N. Verma, F. G. Omenetto, M. C. McAlpine, Nat. Commun. 2012, 3, 763. [136] S. Campuzano, M. Pedrero, G. P. Nikoleli, J. M. Pingarron, D. P. Nikolelis, Biosens. Bioelectron. 2017, 89, 269. [137] S. Badhulika, T. Terse-Thakoor, C. Villarreal, A. Mulchandani, Front. Chem. 2015, 3, 38. [138] Y. Jiang, F. Meng, D. Qi, P. Cai, Z. Yin, F. Shao, H. Zhang, F. Boey, X. Chen, Small 2013, 9, 2260. [139] S. Yin, Y.-L. Wu, B. Hu, Y. Wang, P. Cai, C. K. Tan, D. Qi, L. Zheng, W. R. Leow, N. S. Tan, S. Wang, X. Chen, Adv. Mater. Interfaces 2014, 1, 1300043. [140] S. Wang, H. Wang, J. Jiao, K. J. Chen, G. E. Owens, K. Kamei, J. Sun, D. J. Sherman, C. P. Behrenbruch, H. Wu, H. R. Tseng, Angew. Chem., Int. Ed. 2009, 48, 8970. [141] S. Wang, K. Liu, J. Liu, Z. T. Yu, X. Xu, L. Zhao, T. Lee, E. K. Lee, J. Reiss, Y. K. Lee, L. W. Chung, J. Huang, M. Rettig, D. Seligson, K. N. Duraiswamy, C. K. Shen, H. R. Tseng, Angew. Chem., Int. Ed. 2011, 50, 3084. [142] F. Zhang, Y. Jiang, X. Liu, J. Meng, P. Zhang, H. Liu, G. Yang, G. Li, L. Jiang, L. J. Wan, J. S. Hu, S. Wang, Nano Lett. 2016, 16, 766. [143] H. Liu, X. Liu, J. Meng, P. Zhang, G. Yang, B. Su, K. Sun, L. Chen, D. Han, S. Wang, L. Jiang, Adv. Mater. 2013, 25, 922. [144] N. Kahn, O. Lavie, M. Paz, Y. Segev, H. Haick, Nano Lett. 2015, 15, 7023. [145] C. Chiappini, D. E. Rosa, J. O. Martinez, X. Liu, J. Steele, M. M. Stevens, E. Tasciotti, Nat. Mater. 2015, 14, 532. [146] A. K. Shalek, J. T. Robinson, E. S. Karp, J. S. Lee, D. R. Ahn, M. H. Yoon, A. Sutton, M. Jorgolli, R. S. Gertner, T. S. Gujral, G. MacBeath, E. G. Yang, H. Park, Proc. Natl. Acad. Sci. USA 2010, 107, 1870. [147] Z. Li, J. Song, G. Mantini, M.-Y. Lu, H. Fang, C. Falconi, L.-J. Chen, Z. Wang, Nano Lett. 2009, 9, 3575. [148] Y. Shao, J. Fu, Adv. Mater. 2014, 26, 1494. [149] P. M. Reynolds, R. H. Pedersen, J. Stormonth-Darling, M. J. Dalby, M. O. Riehle, N. Gadegaard, Nano Lett. 2013, 13, 570. [150] S. Choi, J. Park, W. Hyun, J. Kim, J. Kim, Y. B. Lee, C. Song, H. J. Hwang, J. H. Kim, T. Hyeon, D. H. Kim, ACS Nano 2015, 9, 6626. [151] M. R. Prausnitz, R. Langer, Nat. Biotechnol. 2008, 26, 1261.\n© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1605529 (26 of 26)\nAdv. Mater. 2017, 1605529\n[152] J. Yu, Y. Zhang, Y. Ye, R. DiSanto, W. Sun, D. Ranson, F. S. Ligler, J. B. Buse, Z. Gu, Proc. Natl. Acad. Sci. USA 2015, 112, 8260. [153] J. Conde, G. Doria, P. Baptista, J. Drug Delivery 2012, 2012, 751075. [154] A. H. Lu, E. L. Salabas, F. Schuth, Angew. Chem., Int. Ed. 2007, 46, 1222. [155] M. A. Malvindi, V. Brunetti, G. Vecchio, A. Galeone, R. Cingolani, P. P. Pompa, Nanoscale 2012, 4, 486. [156] A. Bianco, K. Kostarelos, M. Prato, Curr. Opin. Chem. Biol. 2005, 9, 674. [157] S. Goenka, V. Sant, S. Sant, J. Controlled Release 2014, 173, 75. [158] N. Oliva, S. Unterman, Y. Zhang, J. Conde, H. S. Song, N. Artzi, Adv. Healthcare Mater. 2015, 4, 1584. [159] A. S. Hoffman, Adv. Drug Delivery Rev. 2013, 65, 10. [160] D. G. Barrett, G. G. Bushnell, P. B. Messersmith, Adv. Healthcare\nMater. 2013, 2, 745. [161] J. Di, S. Yao, Y. Ye, Z. Cui, J. Yu, T. K. Ghosh, Y. Zhu, Z. Gu,\nACS Nano 2015, 9, 9407. [162] C. Martin, Nat. Nanotechnol. 2015, 10, 910. [163] D. Son, J. Lee, S. Qiao, R. Ghaffari, J. Kim, J. Lee, C. Song, S. Kim,\nD. Lee, S. Jun, S. Yang, M. Park, J. Shin, K. Do, M. Lee, K. Kang, C. Hwang, N. Lu, T. Hyeon, D.-H. Kim, Nat. Nanotechnol. 2014, 9, 397. [164] J. Liu, T. M. Fu, Z. Cheng, G. Hong, T. Zhou, L. Jin, M. Duvvuri, Z. Jiang, P. Kruskal, C. Xie, Z. Suo, Y. Fang, C. M. Lieber, Nat. Nanotechnol. 2015, 10, 629. [165] C. Xie, J. Liu, T. M. Fu, X. Dai, W. Zhou, C. M. Lieber, Nat. Mater. 2015, 14, 1286. [166] D. Son, J. Lee, D. J. Lee, R. Ghaffari, S. Yun, S. J. Kim, J. E. Lee, H. R. Cho, S. Yoon, S. Yang, S. Lee, S. Qiao, D. Ling, S. Shin, J. K. Song, J. Kim, T. Kim, H. Lee, J. Kim, M. Soh, N. Lee, C. S. Hwang, S. Nam, N. Lu, T. Hyeon, S. H. Choi, D. H. Kim, ACS Nano 2015, 9, 5937. [167] B. Hu, W. Shi, Y. L. Wu, W. R. Leow, P. Cai, S. Li, X. Chen, Adv. Mater. 2014, 26, 5786.\n[168] B. Tian, J. Liu, T. Dvir, L. Jin, J. H. Tsui, Q. Qing, Z. Suo, R. Langer, D. S. Kohane, C. M. Lieber, Nat. Mater. 2012, 11, 986. [169] R. Feiner, L. Engel, S. Fleischer, M. Malki, I. Gal, A. Shapira, Y. Shacham-Diamand, T. Dvir, Nat. Mater. 2016, 15, 679. [170] S. J. Kim, H. R. Cho, K. W. Cho, S. Qiao, J. S. Rhim, M. Soh, T. Kim, M. K. Choi, C. Choi, I. Park, N. S. Hwang, T. Hyeon, S. H. Choi, N. Lu, D. H. Kim, ACS Nano 2015, 9, 2677. [171] J. Kim, M. Lee, H. J. Shim, R. Ghaffari, H. R. Cho, D. Son, Y. H. Jung, M. Soh, C. Choi, S. Jung, K. Chu, D. Jeon, S. T. Lee, J. H. Kim, S. H. Choi, T. Hyeon, D. H. Kim, Nat. Commun. 2014, 5, 5747. [172] B. Tee, A. Chortos, A. Berndt, A. Nguyen, A. Tom, A. McGuire, Z. Lin, K. Tien, W.-G. Bae, H. Wang, P. Mei, H.-H. Chou, B. Cui, K. Deisseroth, T. Ng, Z. Bao, Science 2015, 350, 313. [173] H. M. Azzazy, M. M. Mansour, S. C. Kazmierczak, Clin. Chem. 2006, 52, 1238. [174] T. Cohen-Karni, Q. Qing, Q. Li, Y. Fang, C. M. Lieber, Nano Lett. 2010, 10, 1098. [175] W. Gao, S. Emaminejad, H. Y. Nyein, S. Challa, K. Chen, A. Peck, H. M. Fahad, H. Ota, H. Shiraki, D. Kiriya, D. H. Lien, G. A. Brooks, R. W. Davis, A. Javey, Nature 2016, 529, 509. [176] A. Sasidharan, L. S. Panchakarla, P. Chandran, D. Menon, S. Nair, C. N. Rao, M. Koyakutty, Nanoscale 2011, 3, 2461. [177] K. A. Tomaszewski, M. W. Radomski, M. J. Santos-Martinez, Nanomedicine 2015, 10, 1451. [178] N. Wang, J. D. Tytell, D. E. Ingber, Nat. Rev. Mol. Cell Biol. 2009, 10, 75. [179] V. Swaminathan, K. Mythreye, T. E. O’Brien, A. Berchuck, G. C. Blobe, R. Superfine, Cancer Res. 2011, 71, 5075. [180] J. Khandare, M. Calderon, N. M. Dagia, R. Haag, Chem. Soc. Rev. 2012, 41, 2824. [181] D. Chimene, D. L. Alge, A. K. Gaharwar, Adv. Mater. 2015, 27, 7261. [182] J. I. Cutler, E. Auyeung, C. A. Mirkin, J. Am. Chem. Soc. 2012, 134,\n1376. [183] Website of BioDigital, the Biodigital Human, www.biodigital.com\n(accessed: March 2017)."
    } ],
    "references" : [ {
      "title" : "Angew",
      "author" : [ "Z. Liu", "M. Winters", "M. Holodniy", "H. Dai" ],
      "venue" : "Chem., Int. Ed. 2007, 46",
      "citeRegEx" : "91",
      "shortCiteRegEx" : null,
      "year" : 2023
    }, {
      "title" : "ACS Nano 2010",
      "author" : [ "A.L. Higginbotham", "D.V. Kosynkin", "A. Sinitskii", "Z. Sun", "J.M. Tour" ],
      "venue" : "4",
      "citeRegEx" : "117",
      "shortCiteRegEx" : null,
      "year" : 2059
    }, {
      "title" : "J",
      "author" : [ "J. Conde", "G. Doria", "P. Baptista" ],
      "venue" : "Drug Delivery 2012",
      "citeRegEx" : "153",
      "shortCiteRegEx" : null,
      "year" : 2012
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "In addition to oligonucleotides, Dai et al.[86,91] also developed SWNTs as nonviral short interfering RNA (siRNA) carriers, which were introduced into primary human cells but were ineffective in transfection.",
      "startOffset" : 43,
      "endOffset" : 50
    }, {
      "referenceID" : 1,
      "context" : "[116] The key challenges for optimal biosensing applications lie in precise size and structure control of graphene foils, GO[117] and rGO,[118] as well as their interface.",
      "startOffset" : 124,
      "endOffset" : 129
    }, {
      "referenceID" : 2,
      "context" : "Nanomaterial-hydrogel hybrids are hydrogel scaffolds embedded with 0D nanomaterials (gold,[153] iron oxide magnetic,[154] silica[155]), 1D nanomaterials (CNT[156]), and 2D nanomaterials (graphene[157]).",
      "startOffset" : 90,
      "endOffset" : 95
    } ],
    "year" : 2017,
    "abstractText" : "DOI: 10.1002/adma.201605529 diseases (e.g., diabetes, metastatic cancers, and Parkinson’s disease). As an alter native solution, recent advances of nanotechnology in biomedicine are showing great promise towards advanced screening and shielding systems/devices. With the increasingly extensive application of nanotechnology in biomedical scenarios, the corresponding nano–bio interfaces are also in the spotlight. At the nano– bio interfaces, nanomaterials interact with biological entities at multiple levels (e.g., proteins, DNA, membranes, organelles, cells, tissues, and organs) through a series of dynamic bio-physicochemical interactions, which can be modulated through the programming of various nanomaterials properties, such as surface chemistry, size, shape, dimension scale and topographic structures.[2,3] It is therefore crucial in the study of nano–bio interfaces to control the surface chemical[4–7] and physical properties,[8–11] as well as functionalities[1,12–14] of nanomaterials, in order to modulate their interfacial interactions with bioentities. Over the past decades, nanomaterials of multiple dimension scales, ranging from zero-dimensional (0D) nanoparticles (NPs),[14] one-dimensional (1D) nanotubes (NTs),[15] and nano wires (NWs),[16] two-dimensional (2D) graphene[17] and nanomembranes (NMs),[18,19] to three-dimensional (3D) architectured nanomaterials,[20] have been programmed on demand as building blocks for the development of functional biointegrated devices (Figure 1). This is because the dimension scale of nanomaterials confers intrinsic advantages as different functional modules in biointegrated devices. For instance, NPs possess excellent penetration capability, versatility in fabrication, and can be given multiple functionalities via surface modification, which renders them the most well-established nanomaterials to be interfaced with biological entities, especially in the fields of drug/gene nanocarriers[8] and diagnostic probes.[14] Meanwhile, 1D and 2D nanomaterials, such as carbon nanotubes (CNTs) and graphene, exhibit unique electrical behaviors, which can open up new frontiers in nano-bioelectronics for boosting the sensitivity of biosensors and understanding of electrophysiology.[21] 2D layered nanomaterials for nanodiagnostics at molecular and cellular interfaces may also enable flexible and stretchable bioelectronics that are compatible with soft or curvilinear biological structures.[19] Lastly, emerging 3D nanomaterials constitute a strategy for incorporating the advantages of the 0D, 1D, and 2D nanomaterials to enable highly-integrated and sophisticated functional devices that are capable of multitasking.[1,22,23] A large amount of evidence has demonstrated the revolutionary role of nanosystems in the screening and shielding of biological systems. The explosive development of interfacing bioentities with programmable nanomaterials has conveyed the intriguing concept of nano–bio interfaces. Here, recent advances in functional biointegrated devices through the precise programming of nano– bio interactions are outlined, especially with regard to the rational assembly of constituent nanomaterials on multiple dimension scales (e.g., nanoparticles, nanowires, layered nanomaterials, and 3D-architectured nanomaterials), in order to leverage their respective intrinsic merits for different functions. Emerging nanotechnological strategies at nano–bio interfaces are also highlighted, such as multimodal diagnosis or “theragnostics”, synergistic and sequential therapeutics delivery, and stretchable and flexible nanoelectronic devices, and their implementation into a broad range of biointegrated devices (e.g., implantable, minimally invasive, and wearable devices). When utilized as functional modules of biointegrated devices, these programmable nano–bio interfaces will open up a new chapter for precision nanomedicine. Biointegrated Devices",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}